DrugRepV Browse Page

DrugRepV browse page allows user to take a glance of the particular antiviral agent.Fields in the webpage is hylerlinked ot various external repositories like DrugBank, PubChem, Clinicaltrials.gov,and PubMed.User can explore the biological, Clinical, Chemical, and Structural details of every repurposed drug candidate.By clicking on the table header arrows, user can sort entries in ascending or descending order.


Total number of Records for NA are 1270

DrugRepV_ID	Antiviral Name	Drug type	Primary Indication	Secondary Indication	Strain	Pathways	Assay	Activity	Clinical Status	References
DrugRepV_0002	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Zika virus	Brazilian strain ZKV2015	NA	NA	Decrease	Approved	29150641
DrugRepV_0026	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Zika virus	GZ01, a recent Asian lineage	NA	NA	Decrease	Approved	29033372
DrugRepV_0074	Sunitinib-Erlotinib	NA	NA	Ebola virus	Mouse adapted strain	NA	NA	Increase	NA	28240606
DrugRepV_0259	Alvespimycin	NA	Cancer	Ebola virus	ME718-1976/Yambuku-Ecran	NA	NA	No significant effect	Investigational	27801778
DrugRepV_0260	Bemcentinib	Anticancer	Cancer	Ebola virus	ME718-1976/Yambuku-Ecran	NA	NA	No significant effect	Investigational	27801778
DrugRepV_0261	NCK-8	NA	NA	Ebola virus	ME718-1976/Yambuku-Ecran	NA	NA	No significant effect	NA	27801778
DrugRepV_0601	Clomiphene Citrate	Genito Urinary System and Sex Hormones	Female infertility	Ebola virus	ma-EBOV	NA	NA	Increase	Approved	23785035
DrugRepV_0602	Toremifene Citrate	Antineoplastic and Immunomodulating Agents	Breast Cancer	Ebola virus	ma-EBOV	NA	NA	Increase	Approved, Investigational	23785035
DrugRepV_0725	Prochlorperazine	Nervous System	Nausea | Vomiting | Schizophrenia	Ebola virus	ma-EBOV	NA	NA	No significant effect	Approved	23577127
DrugRepV_0726	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Ebola virus	ma-EBOV	NA	NA	Increase	Approved	23577127
DrugRepV_0727	Dirithromycin	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	ma-EBOV	NA	NA	No significant effect	Approved	23577127
DrugRepV_0728	Erythromycin ethylsuccinate	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	ma-EBOV	NA	NA	No significant effect	Approved	23577127
DrugRepV_0729	Amlodipine	Cardiovascular agents	Hypertension	Ebola virus	ma-EBOV	NA	NA	No significant effect	Approved	23577127
DrugRepV_0730	Fluoxetine	Nervous System	Major depressive disorder | Bulimia nervosa | Obsessive-compulsive disorder | Premenstrual dysphoric disorder | Panic disorder with or without agoraphobia	Ebola virus	ma-EBOV	NA	NA	No significant effect	Approved, Vet approved	23577127
DrugRepV_0731	Penbutolol	Cardiovascular agents	Arterial hypertension	Ebola virus	ma-EBOV	NA	NA	No significant effect	Approved, Investigational	23577127
DrugRepV_0743	Probenecid	Musculo-Skeletal System	Gout	Influenza virus	A/WSN/33		NA	Increase	Approved, Investigational	23129053
DrugRepV_0750	Favipiravir	Antiviral	Influenza virus	Nipah virus	NiV-Malaysia	NA	NA	Increase	Investigational	29765101
DrugRepV_0756	Favipiravir	Antiviral	Influenza virus	Ebola virus	NA	NA	NA	Increase (7 %)	Investigational	26930627
DrugRepV_0758	Favipiravir	Antiviral	Influenza virus	Ebola virus	NA	NA	NA	Decrease (33 %)	Investigational	26930627
DrugRepV_1892	Seliciclib	Anticancer	Breast cancer | Lung cancer | Lymphoma | Multiple myeloma | Leukemia	Zika virus	FSS13026	NA	NA	Decrease (50 %)	Investigational	27571349
DrugRepV_1893	SNS-032	NA	Cancer	Zika virus	FSS13026	NA	NA	Decrease (50 %)	Investigational	27571349
DrugRepV_1894	PHA-793887	Anticancer	Cancer	Zika virus	FSS13026	NA	NA	Decrease (50 %)	NA	27571349
DrugRepV_1895	AT7519	NA	Cancer	Zika virus	FSS13026	NA	NA	Decrease (50 %)	NA	27571349
DrugRepV_1896	BS-194	Anticancer	Cancer	Zika virus	FSS13026	NA	NA	Decrease (50 %)	NA	27571349
DrugRepV_1897	RGB-286147	NA	NA	Zika virus	FSS13026	NA	NA	Decrease (50 %)	NA	27571349
DrugRepV_1898	Dinaciclib	Anticancer	Cancer	Zika virus	FSS13026	NA	NA	Decrease (50 %)	Investigational	27571349
DrugRepV_1899	Alvocidib	NA	Cancer	Zika virus	FSS13026	NA	NA	Decrease (50 %)	Experimental	27571349
DrugRepV_2957	Doxycycline	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	Clinical isolate of CHIKV (East/Central/South African genotype)	NA	NA	NA	Approved	25970853
DrugRepV_2958	Doxycycline	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	Clinical isolate of CHIKV (East/Central/South African genotype)	NA	NA	NA	Approved	25970853
DrugRepV_3679	NSC 62914	NA	NA	Ebola virus	NA	NA	NA	Decrease	NA	22027648
DrugRepV_3680	NSC 62914	NA	NA	Marburg virus	NA	NA	NA	Decrease	NA	22027648
DrugRepV_3681	N3,N12-bis[2-(morpholin-4-yl)ethyl]-6,15-diazatetracyclo[8.8.0.02,7.011,16]octadeca-1(10),2,4,6,8,11(16),12,14,17-nonaene-3,12-diamine tetrahydrochloride	NA	NA	Ebola virus	Zaire-95	NA	NA	Decrease (50 %)	NA	23012625
DrugRepV_3682	N5,N14-bis[2-(morpholin-4-yl)ethyl]-3,12-bis({[2-(morpholin-4-yl)ethyl]amino})-6,15-diazatetracyclo[8.8.0.02,7.011,16]octadeca-1(10),2,4,6,8,11(16),12,14,17-nonaene-5,14-dicarboxamide; hexakis(trifluoroacet	NA	NA	Ebola virus	Zaire-95	NA	NA	Decrease (50 %)	NA	23012625
DrugRepV_3683	N3,N12-bis[2-(morpholin-4-yl)ethyl]-6,15-diazatetracyclo[8.8.0.02,7.011,16]octadeca-1(10),2,4,6,8,11(16),12,14,17-nonaene-3,12-diamine	NA	NA	Ebola virus	Zaire-95	NA	NA	Decrease (50 %)	NA	23012625
DrugRepV_3684	N3,N12-bis[2-(morpholin-4-yl)ethyl]-6,15-diazatetracyclo[8.8.0.02,7.011,16]octadeca-1(10),2,4,6,8,11(16),12,14,17-nonaene-3,12-diamine tetrahydrochloride	NA	NA	Marburg virus	Ci67	NA	NA	Decrease (50 %)	NA	23012625
DrugRepV_3685	N3,N12-bis[2-(morpholin-4-yl)ethyl]-6,15-diazatetracyclo[8.8.0.02,7.011,16]octadeca-1(10),2,4,6,8,11(16),12,14,17-nonaene-3,12-diamine	NA	NA	Marburg virus	Ci67	NA	NA	Decrease (50 %)	NA	23012625
DrugRepV_3703	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Marburg virus	NA	NA	NA	Decrease (83 %)	Approved	24713118
DrugRepV_3704	6-Azauridine	NA	Cancer	Marburg virus	NA	NA	NA	Decrease (98 %)	NA	24713118
DrugRepV_3705	Chloroquine	Malaria	Malaria	Marburg virus	NA	NA	NA	Decrease (99.9 %)	Approved	24713118
DrugRepV_3706	Imatinib Methanesulfonate Salt	Antineoplastic and Immunomodulating Agents	NA	Marburg virus	NA	NA	NA	Decrease (99 %)	Approved	24713118
DrugRepV_3707	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Ebola virus	NA	NA	NA	Decrease (0 %)	Approved	24713118
DrugRepV_3708	6-Azauridine	NA	Cancer	Ebola virus	NA	NA	NA	Decrease (99 %)	NA	24713118
DrugRepV_3709	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Ebola virus	NA	NA	NA	Decrease (99.9 %)	Approved	24713118
DrugRepV_3710	Imatinib Methanesulfonate Salt	Antineoplastic and Immunomodulating Agents	NA	Ebola virus	NA	NA	NA	Decrease (95 %)	Approved	24713118
DrugRepV_3726	OSU-03012	Anticancer	Brain cancer	Lassa virus	NA	NA	NA	Decrease	NA	25986249
DrugRepV_3727	AZD8055	NA	Cancer	Lassa virus	NA	NA	NA	Decrease	Investigational	25986249
DrugRepV_3728	TWS119	NA	NA	Lassa virus	NA	NA	NA	Decrease	NA	25986249
DrugRepV_3729	SU 4312	NA	NA	Lassa virus	NA	NA	NA	Decrease	NA	25986249
DrugRepV_3730	Falnidamol dihydrochloride	NA	Solid Tumor	Lassa virus	NA	NA	NA	Decrease	Investigational	25986249
DrugRepV_3731	Ki 8751	NA	NA	Lassa virus	NA	NA	NA	Decrease	NA	25986249
DrugRepV_3732	10-DEBC hydrochloride	NA	NA	Lassa virus	NA	NA	NA	Decrease	NA	25986249
DrugRepV_3751	MLS000078751	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3752	MLS000394177	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3753	MLS000534476	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3754	MLS000554255	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3755	MLS000555232	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3756	MLS000730532	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3757	MLS000733230	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3758	MLS000762907	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3759	MLS001101371	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3760	MLS000078751	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3761	MLS000394177	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3762	MLS000534476	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3763	MLS000554255	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3764	MLS000555232	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3765	MLS000730532	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3766	MLS000733230	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3767	MLS000762907	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3768	MLS001101371	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3769	MLS001239325	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3770	MLS001239325	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3771	MLS001030162	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3772	MLS001030162	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3773	MLS000666802	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3774	MLS000666802	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3775	MLS000999960	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3776	MLS000999960	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3777	MLS001173370	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3778	MLS001173370	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3779	MLS001174896	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3780	MLS001174896	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3781	MLS001196083	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3782	MLS001196083	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3783	MLS001239358	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3784	MLS001239358	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3785	MLS001177927	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3786	MLS001177927	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3787	MLS001209453	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3788	MLS001209453	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3789	MLS000580080	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3790	MLS000580080	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3791	MLS000106706	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3792	MLS000106706	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3793	MLS001175455	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3794	MLS001175455	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3795	MLS000772389	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3796	MLS000772389	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3797	MLS000042810	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3798	MLS000042810	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3799	MLS001162808	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3800	MLS001162808	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3801	MLS000684231	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3802	MLS000684231	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3803	MLS000556387	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3804	MLS000556387	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3805	MLS001179278	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3806	MLS001179278	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3807	MLS000567464	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3808	MLS000567464	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3809	MLS000583959	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3810	MLS000583959	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3811	MLS001018888	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3812	MLS001018888	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3813	MLS001047402	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3814	MLS001047402	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3815	MLS001029946	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3816	MLS001029946	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3817	MLS000332573	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3818	MLS000332573	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3819	MLS000936259	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3820	MLS000936259	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3821	MLS000718690	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3822	MLS000718690	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3823	MLS000880330	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3824	MLS000880330	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3825	MLS001207131	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3826	MLS001207131	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3827	MLS000673118	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3828	MLS000673118	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3829	MLS000689481	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3830	MLS000689481	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3831	MLS001179272	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3832	MLS001179272	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3833	MLS002702500	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3834	MLS002702500	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3835	MLS001180408	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3836	MLS000737975	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3837	MLS001237534	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3838	MLS000336293	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3839	MLS000780111	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3840	MLS001179997	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3841	MLS000418057	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3842	MLS000936795	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3843	MLS000092187	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3844	MLS000391391	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3845	MLS000569139	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3846	MLS001045935	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3847	MLS001181479	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3848	MLS000391984	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3849	MLS000063146	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3850	MLS000768081	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3851	MLS000091920	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3852	MLS001150589	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3853	MLS000736237	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3854	Clomiphene	Genito Urinary System and Sex Hormones	Polycystic ovary syndrome	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	Approved	27490565
DrugRepV_3855	Enclomiphene	NA	Male hypogonadism	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	Investigational	27490565
DrugRepV_3856	Zuclomiphene	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27490565
DrugRepV_3862	Favipiravir	Antiviral	Influenza virus	Lassa virus	Ba366	NA	NA	Decrease (50 %)	Investigational	27736754
DrugRepV_3866	Favipiravir	Antiviral	Influenza virus	Ebola virus	Kikwit 1995/E718	NA	NA	Decrease (50 %)	Investigational	27736754
DrugRepV_3893	cp15	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3894	cp15	NA	NA	Marburg virus	Ci67	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3895	cp15	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3896	cp15	NA	NA	Marburg virus	Ci67	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3897	cp19	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3898	cp19	NA	NA	Marburg virus	Ci67	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3899	cp19	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3900	cp19	NA	NA	Marburg virus	Ci67	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3901	cp3	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3902	cp5	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3903	cp11	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3904	cp13	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3905	cp15	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3906	cp16	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3907	cp19	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3908	cp3	NA	NA	Marburg virus	Ci67	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3909	cp5	NA	NA	Marburg virus	Ci67	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3910	cp11	NA	NA	Marburg virus	Ci67	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3911	cp13	NA	NA	Marburg virus	Ci67	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3912	cp15	NA	NA	Marburg virus	Ci67	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3913	cp16	NA	NA	Marburg virus	Ci67	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3914	cp19	NA	NA	Marburg virus	Ci67	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3915	cp3	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3916	cp5	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3917	cp11	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3918	cp13	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3919	cp15	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3920	cp16	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3921	cp19	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3922	CBS1129	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3923	CBS1130	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3924	CBS1131	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3925	CBS1132	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3926	CBS1133	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3927	CBS1134	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3928	CBS1135	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3929	CBS1136	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3930	CBS1137	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3931	CBS1138	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3932	CBS1139	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3935	Favipiravir	Antiviral	Influenza virus	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	Investigational	29289664
DrugRepV_3936	Favipiravir	Antiviral	Influenza virus	Ebola virus	Makona	NA	NA	Decrease (50 %)	Investigational	29289664
DrugRepV_3937	Favipiravir	Antiviral	Influenza virus	Marburg virus	Ci67	NA	NA	Decrease (50 %)	Investigational	29289664
DrugRepV_3953	12N-p-dichlorobenzyl aloperine	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3954	12N-o-methylbenzyl aloperine dihydrochloride	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3955	12N-2,4-dichlorobenzyl aloperine dihydrochloride	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3956	12N-3,5 -dichlorobenzyl aloperine dihydrochloride	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3957	12N-3,4-dichlorobenzyl aloperine dihydrochloride	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3958	12N-m-methoxybenzyl aloperine dihydrochloride	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3959	12N-benzyl aloperine dihydrochloride	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3960	12N-p-trifluoromethoxylbenzyl aloperine dihydrochloride	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3961	12N-p-fluorobenzyl aloperine dihydrochloride	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3962	12N-3,5-dichlorobenzoyl aloperine	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3963	12N-p-chlorobenzoyl aloperine	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3964	12N-3,4-dichlorobenzoyl aloperine	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3965	12N-3,4-dichlorobenzenesulfonyl aloperine	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3966	12N-3,5-dichlorobenzenesulfonyl aloperine	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3967	12N-o-thiophenesulfonyl aloperine	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3968	12N-m-cyanobenzenesulfonyl aloperine	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3969	12N-p-chlorobenzenesulfonyl aloperine	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3970	12N-p-chlorophenylethyl aloperine dihydrochloride	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3971	12N-3,4-dichlorophenylethyl aloperine dihydrochloride	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3972	12N-3,5-dichlorophenylethyl aloperine dihydrochloride	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3973	12N-3,4-dichlorohydrocinnamyl aloperine dihydrochloride	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3974	12N-3,5-dichlorohydrocinnamyl aloperine dihydrochloride	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3975	12N-p-chlorohydrocinnamyl aloperine dihydrochloride	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3976	12N-p-dichlorobenzyl aloperine	NA	NA	Marburg virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3977	12N-o-methylbenzyl aloperine dihydrochloride	NA	NA	Marburg virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3978	12N-2,4-dichlorobenzyl aloperine dihydrochloride	NA	NA	Marburg virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3979	12N-3,5 -dichlorobenzyl aloperine dihydrochloride	NA	NA	Marburg virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3980	12N-3,4-dichlorobenzyl aloperine dihydrochloride	NA	NA	Marburg virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3981	12N-m-methoxybenzyl aloperine dihydrochloride	NA	NA	Marburg virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3982	12N-benzyl aloperine dihydrochloride	NA	NA	Marburg virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3983	12N-p-trifluoromethoxylbenzyl aloperine dihydrochloride	NA	NA	Marburg virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3984	12N-p-fluorobenzyl aloperine dihydrochloride	NA	NA	Marburg virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3985	12N-3,5-dichlorobenzoyl aloperine	NA	NA	Marburg virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3986	12N-p-chlorobenzoyl aloperine	NA	NA	Marburg virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3987	12N-3,4-dichlorobenzoyl aloperine	NA	NA	Marburg virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3988	12N-3,4-dichlorobenzenesulfonyl aloperine	NA	NA	Marburg virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3989	12N-3,5-dichlorobenzenesulfonyl aloperine	NA	NA	Marburg virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3990	12N-o-thiophenesulfonyl aloperine	NA	NA	Marburg virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3991	12N-m-cyanobenzenesulfonyl aloperine	NA	NA	Marburg virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3992	12N-p-chlorobenzenesulfonyl aloperine	NA	NA	Marburg virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_4005	FGI-103	NA	NA	Ebola virus	Zaire	NA	NA	Decrease	NA	20211898
DrugRepV_4298	Baicalein	Plant extract	Influenza	Chikungunya virus	NA	NA	NA	Decrease (50 %)	Phase II	27460167
DrugRepV_4299	Fisetin	NA	Frail Elderly Syndrome	Chikungunya virus	NA	NA	NA	Decrease (50 %)	Experimental	27460167
DrugRepV_4300	Quercetagetin	NA	NA	Chikungunya virus	NA	NA	NA	Decrease (50 %)	NA	27460167
DrugRepV_4301	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Chikungunya virus	NA	NA	NA	Decrease (50 %)	Approved	27460167
DrugRepV_4471	Brincidofovir	Antiviral	Viral infections	Ebola virus	EBOV-GFP	NA	NA	Decrease (50 %)	Investigational	26526586
DrugRepV_4472	Brincidofovir	Antiviral	Viral infections	Ebola virus	EBOV-Gluc	NA	NA	Decrease (50 %)	Investigational	26526586
DrugRepV_4473	Brincidofovir	Antiviral	Viral infections	Ebola virus	EBOV-GFP	NA	NA	Decrease (50 %)	Investigational	26526586
DrugRepV_4474	Brincidofovir	Antiviral	Viral infections	Ebola virus	EBOV-GFP	NA	NA	Decrease (50 %)	Investigational	26526586
DrugRepV_4475	Brincidofovir	Antiviral	Viral infections	Ebola virus	EBOV-GFP	NA	NA	Decrease (50 %)	Investigational	26526586
DrugRepV_4476	Brincidofovir	Antiviral	Viral infections	Ebola virus	EBOV-GFP	NA	NA	Decrease (50 %)	Investigational	26526586
DrugRepV_4477	Brincidofovir	Antiviral	Viral infections	Ebola virus	EBOV-GFP	NA	NA	Decrease (50 %)	Investigational	26526586
DrugRepV_4479	Brincidofovir	Antiviral	Viral infections	Ebola virus	Makona	NA	NA	Decrease (50 %)	Investigational	26526586
DrugRepV_4497	Ranpirnase	Anticancer	Cancer	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	Investigational	27350309
DrugRepV_4499	Ranpirnase	Anticancer	Cancer	Ebola virus	Kikwit	NA	NA	Increase	Investigational	27350309
DrugRepV_4500	(1S,2R,5S)-5-{4-amino-1H-imidazo[4,5-c]pyridin-1-yl}-4-fluoro-3-(hydroxymethyl)cyclopent-3-ene-1,2-diol	NA	NA	Ebola virus	Zaire	NA	NA	Decrease (50 %)	NA	30385162
DrugRepV_4501	(1S,2R,5R)-5-(6-amino-9H-purin-9-yl)-3-(hydroxymethyl)cyclopent-3-ene-1,2-diol	NA	NA	Ebola virus	Zaire	NA	NA	Decrease (50 %)	NA	30385162
DrugRepV_4502	(1S,2R,5R)-5-{4-amino-1H-imidazo[4,5-c]pyridin-1-yl}-3-(hydroxymethyl)cyclopent-3-ene-1,2-diol	NA	NA	Ebola virus	Zaire	NA	NA	Decrease (50 %)	NA	30385162
DrugRepV_4503	(1R,2S,5R)-3-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)cyclopent-3-ene-1,2-diol	NA	NA	Ebola virus	Zaire	NA	NA	Decrease (50 %)	NA	30385162
DrugRepV_4504	(1R,2S,5R)-3-{4-amino-1H-imidazo[4,5-c]pyridin-1-yl}-5-(hydroxymethyl)cyclopent-3-ene-1,2-diol	NA	NA	Ebola virus	Zaire	NA	NA	Decrease (50 %)	NA	30385162
DrugRepV_4505	(1S,2R,5S)-5-{4-amino-1H-imidazo[4,5-c]pyridin-1-yl}-4-fluoro-3-(hydroxymethyl)cyclopent-3-ene-1,2-diol	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	30385162
DrugRepV_4506	(1S,2R,5R)-5-(6-amino-9H-purin-9-yl)-3-(hydroxymethyl)cyclopent-3-ene-1,2-diol	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	30385162
DrugRepV_4507	(1S,2R,5R)-5-{4-amino-1H-imidazo[4,5-c]pyridin-1-yl}-3-(hydroxymethyl)cyclopent-3-ene-1,2-diol	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	30385162
DrugRepV_4508	(1R,2S,5R)-3-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)cyclopent-3-ene-1,2-diol	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	30385162
DrugRepV_4509	(1R,2S,5R)-3-{4-amino-1H-imidazo[4,5-c]pyridin-1-yl}-5-(hydroxymethyl)cyclopent-3-ene-1,2-diol	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	30385162
DrugRepV_4510	(1S,2R,5S)-5-(6-amino-9H-purin-9-yl)-4-fluoro-3-(hydroxymethyl)cyclopent-3-ene-1,2-diol	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	30385162
DrugRepV_4511	(1S,2R,5S)-5-{4-amino-1H-imidazo[4,5-c]pyridin-1-yl}-4-fluoro-3-(hydroxymethyl)cyclopent-3-ene-1,2-diol	NA	NA	Influenza virus	NA		NA	Decrease (50 %)	NA	30385162
DrugRepV_4512	Favipiravir	Antiviral	Influenza virus	Ebola virus	NA	NA	NA	Increase	Investigational	30275474
DrugRepV_4513	Remdesivir	Antiviral	Hepatitis C | Ebola	Ebola virus	NA	NA	NA	Increase	Experimental	30275474
DrugRepV_4514	Favipiravir	Antiviral	Influenza virus	Ebola virus	NA	NA	NA	Increase	Investigational	29584730
DrugRepV_4515	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Influenza virus	NA		NA	Decrease (50 %)	Approved	15200845
DrugRepV_4516	Zanamivir	Antiinfectives For Systemic Use	Influenza virus	Influenza virus	NA		NA	Decrease (50 %)	Approved	15200845
DrugRepV_4517	Oseltamivir	Antiinfectives For Systemic Use	Influenza A/B virus	Influenza virus	NA		NA	Decrease (50 %)	Approved	15200845
DrugRepV_4518	Amantadine	Nervous System	Influenza and Parkinson Disease	Influenza virus	NA		NA	Decrease (50 %)	Approved	15200845
DrugRepV_4540	1-[4,5-dihydroxy-3-(hydroxymethyl)cyclopent-2-en-1-yl]-1H-1,2,4-triazole-3-carboxamide	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	16451078
DrugRepV_4541	1-[4,5-dihydroxy-3-(hydroxymethyl)cyclopent-2-en-1-yl]-1H-imidazole-4-carboxamide	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	16451078
DrugRepV_4542	1-[4,5-dihydroxy-3-(hydroxymethyl)cyclopent-2-en-1-yl]-1H-1,2,3-triazole-4-carboxamide	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	16451078
DrugRepV_4543	Alferon	NA	Condylomata acuminata	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	Approved	16451078
DrugRepV_4544	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	Approved	15961169
DrugRepV_4545	AZT	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	Approved	15961169
DrugRepV_4546	Lopinavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	Approved	15961169
DrugRepV_4547	Aurintricarboxylic acid	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	15961169
DrugRepV_4548	DS5000	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	15961169
DrugRepV_4549	Novaron	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	15961169
DrugRepV_4550	Glycirrhizin	Bile And Liver Therapy	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	15961169
DrugRepV_4551	S-Nitroso-N-acetylpenicillamine	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	15961169
DrugRepV_4552	7-(benzyloxy)-2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-4H-chromen-4-one	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	22297745
DrugRepV_4553	2-(3,4-dihydroxyphenyl)-7-[(2-fluorophenyl)methoxy]-3,5-dihydroxy-4H-chromen-4-one	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	22297745
DrugRepV_4554	7-[(2-chlorophenyl)methoxy]-2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-4H-chromen-4-one	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	22297745
DrugRepV_4555	7-[(2-bromophenyl)methoxy]-2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-4H-chromen-4-one	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	22297745
DrugRepV_4556	2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-7-[(2-iodophenyl)methoxy]-4H-chromen-4-one	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	22297745
DrugRepV_4557	2-({[2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-4-oxo-4H-chromen-7-yl]oxy}methyl)benzonitrile	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	22297745
DrugRepV_4558	2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-7-[(2-nitrophenyl)methoxy]-4H-chromen-4-one	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	22297745
DrugRepV_4559	2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-7-[(2-methylphenyl)methoxy]-4H-chromen-4-one	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	22297745
DrugRepV_4560	2-(3,4-dihydroxyphenyl)-7-[(3-fluorophenyl)methoxy]-3,5-dihydroxy-4H-chromen-4-one	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	22297745
DrugRepV_4561	7-[(3-chlorophenyl)methoxy]-2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-4H-chromen-4-one	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	22297745
DrugRepV_4562	7-[(3-bromophenyl)methoxy]-2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-4H-chromen-4-one	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	22297745
DrugRepV_4563	2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-7-[(3-iodophenyl)methoxy]-4H-chromen-4-one	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	22297745
DrugRepV_4564	3-({[2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-4-oxo-4H-chromen-7-yl]oxy}methyl)benzonitrile	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	22297745
DrugRepV_4565	2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-7-[(3-nitrophenyl)methoxy]-4H-chromen-4-one	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	22297745
DrugRepV_4566	2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-7-[(3-methylphenyl)methoxy]-4H-chromen-4-one	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	22297745
DrugRepV_4567	2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-7-[(3-methoxyphenyl)methoxy]-4H-chromen-4-one	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	22297745
DrugRepV_4568	2-(3,4-dihydroxyphenyl)-7-[(4-fluorophenyl)methoxy]-3,5-dihydroxy-4H-chromen-4-one	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	22297745
DrugRepV_4569	7-[(4-chlorophenyl)methoxy]-2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-4H-chromen-4-one	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	22297745
DrugRepV_4570	7-[(4-bromophenyl)methoxy]-2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-4H-chromen-4-one	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	22297745
DrugRepV_4571	2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-7-[(4-iodophenyl)methoxy]-4H-chromen-4-one	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	22297745
DrugRepV_4572	4-({[2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-4-oxo-4H-chromen-7-yl]oxy}methyl)benzonitrile	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	22297745
DrugRepV_4573	2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-7-[(4-nitrophenyl)methoxy]-4H-chromen-4-one	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	22297745
DrugRepV_4574	2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-7-[(4-methylphenyl)methoxy]-4H-chromen-4-one	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	22297745
DrugRepV_4575	2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-7-[(4-methoxyphenyl)methoxy]-4H-chromen-4-one	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	22297745
DrugRepV_4603	1H-1,2,3-benzotriazol-1-yl 1H-indole-5-carboxylate	NA	NA	Severe acute respiratory syndrome coronavirus	Urbani	NA	NA	Decrease (50 %)	NA	18796354
DrugRepV_4604	5-chloropyridin-3-yl 1H-indole-5-carboxylate	NA	NA	Severe acute respiratory syndrome coronavirus	Urbani	NA	NA	Decrease (50 %)	NA	18796354
DrugRepV_4605	5-chloropyridin-3-yl 1-acetyl-1H-indole-5-carboxylate	NA	NA	Severe acute respiratory syndrome coronavirus	Urbani	NA	NA	Decrease (50 %)	NA	18796354
DrugRepV_4606	5-chloropyridin-3-yl 1-(4-methylbenzenesulfonyl)-1H-indole-5-carboxylate	NA	NA	Severe acute respiratory syndrome coronavirus	Urbani	NA	NA	Decrease (50 %)	NA	18796354
DrugRepV_4607	5-chloropyridin-3-yl 1-(3-nitrobenzenesulfonyl)-1H-indole-5-carboxylate	NA	NA	Severe acute respiratory syndrome coronavirus	Urbani	NA	NA	Decrease (50 %)	NA	18796354
DrugRepV_4608	5-chloropyridin-3-yl1H-indole-6-carboxylate	NA	NA	Severe acute respiratory syndrome coronavirus	Urbani	NA	NA	Decrease (50 %)	NA	18796354
DrugRepV_4609	5-chloropyridin-3-yl 1H-indole-4-carboxylate	NA	NA	Severe acute respiratory syndrome coronavirus	Urbani	NA	NA	Decrease (50 %)	NA	18796354
DrugRepV_4610	5-chloropyridin-3-yl 1-acetyl-1H-indole-4-carboxylate	NA	NA	Severe acute respiratory syndrome coronavirus	Urbani	NA	NA	Decrease (50 %)	NA	18796354
DrugRepV_4611	5-chloropyridin-3-yl 1H-indole-7-carboxylate	NA	NA	Severe acute respiratory syndrome coronavirus	Urbani	NA	NA	Decrease (50 %)	NA	18796354
DrugRepV_4612	5-chloropyridin-3-yl (6R)-6-{[(tert-butoxy)carbonyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate	NA	NA	Severe acute respiratory syndrome coronavirus	Urbani	NA	NA	Decrease (50 %)	NA	18796354
DrugRepV_4613	5-chloropyridin-3-yl 2-acetyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylate	NA	NA	Severe acute respiratory syndrome coronavirus	Urbani	NA	NA	Decrease (50 %)	NA	18796354
DrugRepV_4682	Arbidol	NA	Viral infection	Zika virus	MR766	NA	NA	Decrease (50 %)	Investigational	29895962
DrugRepV_4773	6-Mercaptopurine	Antineoplastic and Immunomodulating Agents	Acute lymphatic leukemia	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	Approved	25542975
DrugRepV_4774	Thioguanine	Antineoplastic and Immunomodulating Agents	Acute leukemia	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	Approved	25542975
DrugRepV_4775	N-ethylmaleimide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	Experimental	25542975
DrugRepV_4776	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	Approved	25542975
DrugRepV_4784	2-(5-{[(4Z)-1-(3-carboxyphenyl)-3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)-4-chlorobenzoic acid	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4785	2-(5-{[(4Z)-1-(3-carboxyphenyl)-5-oxo-3-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)-4-chlorobenzoic acid	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4786	2-(5-{[(4Z)-1-(3-carboxyphenyl)-5-oxo-3-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)benzoic acid	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4787	2-(5-{[(4Z)-1-(3-carboxyphenyl)-5-oxo-3-phenyl-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)-4-chlorobenzoic acid	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4788	4-chloro-2-(5-{[(4Z)-3-methyl-5-oxo-1-phenyl-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)benzoic acid	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4789	4-chloro-2-(5-{[(4Z)-5-oxo-1,3-diphenyl-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)benzoic acid	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4790	4-chloro-2-(5-{[(4Z)-1-(4-fluorophenyl)-5-oxo-3-phenyl-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)benzoic acid	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4791	4-chloro-2-(5-{[(4Z)-5-oxo-3-phenyl-1-[4-(propan-2-yl)phenyl]-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)benzoic acid	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4792	2-(5-{[(4Z)-1-(4-tert-butylphenyl)-5-oxo-3-phenyl-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)-4-chlorobenzoic acid	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4793	(4Z)-1,3-diphenyl-4-[(5-phenylfuran-2-yl)methylidene]-4,5-dihydro-1H-pyrazol-5-one	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4794	3-[(4Z)-5-oxo-3-phenyl-4-[(5-phenylfuran-2-yl)methylidene]-4,5-dihydro-1H-pyrazol-1-yl]benzoic acid	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4795	3-[(4Z)-3-methyl-5-oxo-4-[(5-phenylfuran-2-yl)methylidene]-4,5-dihydro-1H-pyrazol-1-yl]benzoic acid	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4796	2-(5-{[(4Z)-5-oxo-1,3-diphenyl-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)benzoic acid	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4797	2-(5-{[(4Z)-1-(4-fluorophenyl)-5-oxo-3-phenyl-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)benzoic acid	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4798	2-(5-{[(4Z)-5-oxo-3-phenyl-1-[4-(propan-2-yl)phenyl]-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)benzoic acid	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4799	2-(5-{[(4Z)-1-(4-tert-butylphenyl)-5-oxo-3-phenyl-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)benzoic acid	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4800	2-(5-{[(4Z)-1-(4-cyanophenyl)-5-oxo-3-phenyl-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)benzoic acid	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4801	2-(5-{[(4Z)-1-(4-methoxyphenyl)-5-oxo-3-phenyl-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)benzoicacid	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4802	3-[(4Z)-4-[(furan-2-yl)methylidene]-5-oxo-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl]benzoic acid	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4803	2-(5-{[(4Z)-1-(3-carboxyphenyl)-3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)-4-chlorobenzoic acid	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4804	2-(5-{[(4Z)-1-(3-carboxyphenyl)-5-oxo-3-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)-4-chlorobenzoic acid	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4805	2-(5-{[(4Z)-1-(3-carboxyphenyl)-5-oxo-3-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)benzoic acid	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4806	2-(5-{[(4Z)-1-(3-carboxyphenyl)-5-oxo-3-phenyl-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)-4-chlorobenzoic acid	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4807	4-chloro-2-(5-{[(4Z)-3-methyl-5-oxo-1-phenyl-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)benzoic acid	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4808	4-chloro-2-(5-{[(4Z)-5-oxo-1,3-diphenyl-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)benzoic acid	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4809	4-chloro-2-(5-{[(4Z)-1-(4-fluorophenyl)-5-oxo-3-phenyl-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)benzoic acid	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4810	4-chloro-2-(5-{[(4Z)-5-oxo-3-phenyl-1-[4-(propan-2-yl)phenyl]-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)benzoic acid	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4811	2-(5-{[(4Z)-1-(4-tert-butylphenyl)-5-oxo-3-phenyl-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)-4-chlorobenzoic acid	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4812	(4Z)-1,3-diphenyl-4-[(5-phenylfuran-2-yl)methylidene]-4,5-dihydro-1H-pyrazol-5-one	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4813	3-[(4Z)-5-oxo-3-phenyl-4-[(5-phenylfuran-2-yl)methylidene]-4,5-dihydro-1H-pyrazol-1-yl]benzoic acid	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4814	3-[(4Z)-3-methyl-5-oxo-4-[(5-phenylfuran-2-yl)methylidene]-4,5-dihydro-1H-pyrazol-1-yl]benzoic acid	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4815	2-(5-{[(4Z)-5-oxo-1,3-diphenyl-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)benzoic acid	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4816	2-(5-{[(4Z)-1-(4-fluorophenyl)-5-oxo-3-phenyl-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)benzoic acid	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4817	2-(5-{[(4Z)-5-oxo-3-phenyl-1-[4-(propan-2-yl)phenyl]-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)benzoic acid	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4818	2-(5-{[(4Z)-1-(4-tert-butylphenyl)-5-oxo-3-phenyl-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)benzoic acid	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4819	2-(5-{[(4Z)-1-(4-cyanophenyl)-5-oxo-3-phenyl-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)benzoic acid	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4820	2-(5-{[(4Z)-1-(4-methoxyphenyl)-5-oxo-3-phenyl-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)benzoicacid	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4821	3-[(4Z)-4-[(furan-2-yl)methylidene]-5-oxo-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl]benzoic acid	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4833	8-(trifluoromethyl)-9H-purin-6-amine	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	25746232
DrugRepV_4834	8-(trifluoromethyl)-9H-purin-6-amine	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	25746232
DrugRepV_4835	5-amino-2-methyl-N-[(1R)-1-(naphthalen-1-yl)ethyl]benzamide	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	25746232
DrugRepV_4836	2-methyl-5-[(methylamino)methyl]-N-[(1R)-1-(naphthalen-1-yl)ethyl]benzamide	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	25746232
DrugRepV_4837	N-[(2H-1,3-benzodioxol-5-yl)methyl]-1-[(1R)-1-(naphthalen-1-yl)ethyl]piperidine-4-carboxamide	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	25746232
DrugRepV_4838	N-[(2H-1,3-benzodioxol-5-yl)methyl]-1-[(1S)-1-(naphthalen-1-yl)ethyl]piperidine-4-carboxamide	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	25746232
DrugRepV_4839	N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(thiophen-3-yl)methyl]acetamido]phenyl}thiophene-2-carboxamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4840	N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(thiophen-3-yl)methyl]acetamido]phenyl}benzamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4841	N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(thiophen-3-yl)methyl]acetamido]phenyl}cyclobutanecarboxamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4842	N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(thiophen-3-yl)methyl]acetamido]phenyl}cyclohexanecarboxamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4843	2-(1H-1,2,3-benzotriazol-1-yl)-N-[4-(pyridin-4-yl)phenyl]-N-[(thiophen-3-yl)methyl]acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4844	N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(thiophen-3-yl)methyl]acetamido]phenyl}-2-methylpropanamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4845	2-(1H-1,2,3-benzotriazol-1-yl)-N-[4-(2-methoxypyridin-3-yl)phenyl]-N-[(thiophen-3-yl)methyl]acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4846	N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(thiophen-3-yl)methyl]acetamido]phenyl}cyclopropanecarboxamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4847	2-(1H-1,2,3-benzotriazol-1-yl)-N-[4-(2-methoxypyrimidin-5-yl)phenyl]-N-[(thiophen-3-yl)methyl]acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4848	N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(thiophen-3-yl)methyl]acetamido]phenyl}-2,2,2-trifluoroacetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4849	2-(1H-1,2,3-benzotriazol-1-yl)-N-[4-(pyridin-3-yl)phenyl]-N-[(thiophen-3-yl)methyl]acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4850	2-methylpropyl N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(thiophen-3-yl)methyl]acetamido]phenyl}carbamate	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4851	N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(thiophen-3-yl)methyl]acetamido]phenyl}propanamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4852	N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(thiophen-3-yl)methyl]acetamido]phenyl}-2-methoxyacetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4853	N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(thiophen-3-yl)methyl]acetamido]phenyl}-3-methoxypropanamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4854	2-(1H-1,2,3-benzotriazol-1-yl)-N-[4-(methylamino)phenyl]-N-[(thiophen-3-yl)methyl]acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4855	2-(1H-1,2,3-benzotriazol-1-yl)-N-[4-(benzylamino)phenyl]-N-[(thiophen-3-yl)methyl]acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4856	N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(thiophen-3-yl)methyl]acetamido]phenyl}-2,2-dimethylpropanamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4857	2-methyl-N-(4-{N-[(thiophen-3-yl)methyl]-2-(1H-1,2,3-triazol-1-yl)acetamido}phenyl)propanamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4858	methyl 2-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(thiophen-3-yl)methyl]acetamido]phenyl}-1H-pyrrole-1-carboxylate	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (31 %)	NA	26190463
DrugRepV_4859	2-(1H-1,2,3-benzotriazol-1-yl)-N-{[1,1-biphenyl]-4-yl}-N-[(thiophen-3-yl)methyl]acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (21 %)	NA	26190463
DrugRepV_4860	N-(4-tert-butylphenyl)-N-[(pyridin-3-yl)methyl]-1H-imidazole-4-carboxamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (49 %)	NA	26190463
DrugRepV_4861	2-methyl-N-{4-[2-(4-phenyl-1H-1,2,3-triazol-1-yl)-N-[(thiophen-3-yl)methyl]acetamido]phenyl}propanamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (25 %)	NA	26190463
DrugRepV_4862	N-(4-tert-butylphenyl)-N-[(pyridin-3-yl)methyl]furan-3-carboxamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (24 %)	NA	26190463
DrugRepV_4863	2-methyl-N-(4-{N-[(thiophen-3-yl)methyl]-2-[4-(trimethylsilyl)-1H-1,2,3-triazol-1-yl]acetamido}phenyl)propanamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (15 %)	NA	26190463
DrugRepV_4864	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(1-methyl-1H-imidazol-4-yl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4865	N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(benzylcarbamoyl)(3-fluorophenyl)methyl]acetamido]phenyl}-2-methylpropanamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4866	2-[2-(1H-1,2,3-benzotriazol-1-yl)-N-(4-acetamidophenyl)acetamido]-N-tert-butyl-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4867	N-tert-butyl-2-(N-{2-cyano-[1,1-biphenyl]-4-yl}-1-(furan-2-yl)formamido)-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4868	N-tert-butyl-2-[N-(4-tert-butylphenyl)-2-(1H-indol-3-yl)acetamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4869	N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(tert-butylcarbamoyl)(thiophen-3-yl)methyl]acetamido]phenyl}cyclopropanecarboxamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4870	N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(benzylcarbamoyl)(3-fluorophenyl)methyl]acetamido]phenyl}cyclobutanecarboxamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4871	N-tert-butyl-2-(N-{4-[(fluoromethoxy)methyl]phenyl}-2-(1H-indol-3-yl)acetamido)-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4872	N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(tert-butylcarbamoyl)(thiophen-3-yl)methyl]acetamido]phenyl}benzamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4873	N-tert-butyl-2-[2-(1H-indol-3-yl)-N-[4-(propan-2-yl)phenyl]acetamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4874	N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(benzylcarbamoyl)(3-fluorophenyl)methyl]acetamido]phenyl}cyclopropanecarboxamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4875	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(1,3-oxazol-5-yl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4876	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(1H-imidazol-4-yl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4877	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(furan-2-yl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4878	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(1H-imidazol-4-yl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4879	N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(tert-butylcarbamoyl)(thiophen-3-yl)methyl]acetamido]phenyl}-1,2-oxazole-5-carboxamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4880	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(1H-imidazol-4-yl)formamido]-2-(pyrimidin-5-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4881	N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(tert-butylcarbamoyl)(thiophen-3-yl)methyl]acetamido]phenyl}-2-methylpropanamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4882	N-{4-[2-(1H-1,3-benzodiazol-1-yl)-N-[(tert-butylcarbamoyl)(thiophen-3-yl)methyl]acetamido]phenyl}propanamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4883	2-[2-(1H-1,2,3-benzotriazol-1-yl)-N-(4-acetamidophenyl)acetamido]-N-tert-butyl-2-(3-fluorophenyl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4884	2-[N-(4-aminophenyl)-2-(1H-1,2,3-benzotriazol-1-yl)acetamido]-N-tert-butyl-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4885	(2S)-N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(furan-2-yl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4886	N-{4-[2-(1H-1,3-benzodiazol-1-yl)-N-[(tert-butylcarbamoyl)(thiophen-3-yl)methyl]acetamido]phenyl}-2-methylpropanamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4887	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(1,3-oxazol-5-yl)formamido]-2-(pyrimidin-5-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4888	N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(tert-butylcarbamoyl)(thiophen-3-yl)methyl]acetamido]phenyl}thiophene-2-carboxamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (26 %)	NA	26190463
DrugRepV_4889	N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(tert-butylcarbamoyl)(thiophen-3-yl)methyl]acetamido]phenyl}cyclobutanecarboxamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (20 %)	NA	26190463
DrugRepV_4890	N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(tert-butylcarbamoyl)(thiophen-3-yl)methyl]acetamido]phenyl}cyclohexanecarboxamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (21 %)	NA	26190463
DrugRepV_4891	N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(tert-butylcarbamoyl)(thiophen-3-yl)methyl]acetamido]phenyl}propanamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (34 %)	NA	26190463
DrugRepV_4892	N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(tert-butylcarbamoyl)(thiophen-3-yl)methyl]acetamido]phenyl}-2,2-dimethylpropanamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (18 %)	NA	26190463
DrugRepV_4893	N-tert-butyl-2-[1-(4-cyanophenyl)-N-(4-fluorophenyl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (53 %)	NA	26190463
DrugRepV_4894	N-tert-butyl-2-[N-cyclopropyl-2-(1H-indol-3-yl)acetamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (49 %)	NA	26190463
DrugRepV_4895	N-tert-butyl-2-[N-cyclopropyl-2-(pyridin-3-yl)acetamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (48 %)	NA	26190463
DrugRepV_4896	N-tert-butyl-2-[N-(4-fluorophenyl)-2-(pyridin-3-yl)acetamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (47 %)	NA	26190463
DrugRepV_4897	N-tert-butyl-2-[N-cyclopropyl-1-(furan-2-yl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (43 %)	NA	26190463
DrugRepV_4898	N-tert-butyl-2-{N-cyclopropyl-1-[5-(trifluoromethyl)pyridin-2-yl]formamido}-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (42 %)	NA	26190463
DrugRepV_4899	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(pyrazin-2-yl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (41 %)	NA	26190463
DrugRepV_4900	N-tert-butyl-2-{N-[4-(propan-2-yl)phenyl]-2-(pyridin-3-yl)acetamido}-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (41 %)	NA	26190463
DrugRepV_4901	N-tert-butyl-2-[N-(4-fluorophenyl)-2-(1H-indol-3-yl)acetamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (41 %)	NA	26190463
DrugRepV_4902	N-tert-butyl-2-[N-(4-fluorophenyl)-1-(furan-2-yl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (41 %)	NA	26190463
DrugRepV_4903	(2S)-2-{N-[4-(butan-2-yl)phenyl]-1-(furan-2-yl)formamido}-N-tert-butyl-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (39 %)	NA	26190463
DrugRepV_4904	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(furan-2-yl)formamido]-2-(pyridazin-4-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (35 %)	NA	26190463
DrugRepV_4905	N-tert-butyl-2-[1-(3-methylfuran-2-yl)-N-[4-(propan-2-yl)phenyl]formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (36 %)	NA	26190463
DrugRepV_4906	N-tert-butyl-2-[1-(furan-2-yl)-N-[4-(propan-2-yl)phenyl]formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (34 %)	NA	26190463
DrugRepV_4907	2-[2-(1H-1,2,3-benzotriazol-1-yl)-N-(4-acetamidophenyl)acetamido]-2-(3-fluorophenyl)-N-phenylacetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (32 %)	NA	26190463
DrugRepV_4908	N-tert-butyl-2-{N-[4-(difluoromethoxy)phenyl]-1-(furan-2-yl)formamido}-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (31 %)	NA	26190463
DrugRepV_4909	N-tert-butyl-2-[N-(4-tert-butylphenyl)-2-(1H-indol-3-yl)acetamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (31 %)	NA	26190463
DrugRepV_4910	N-tert-butyl-2-[1-(furan-2-yl)-N-[4-(1H-pyrrol-3-yl)phenyl]formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (31 %)	NA	26190463
DrugRepV_4911	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(1,3-oxazol-2-yl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (30 %)	NA	26190463
DrugRepV_4912	N-tert-butyl-2-[N-(4-fluorophenyl)-1-[5-(trifluoromethyl)pyridin-2-yl]formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (29 %)	NA	26190463
DrugRepV_4913	N-tert-butyl-2-{N-[4-(fluoromethoxy)phenyl]-2-(pyridin-3-yl)acetamido}-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (29 %)	NA	26190463
DrugRepV_4914	[(tert-butylcarbamoyl)(pyridin-3-yl)methyl](4-tert-butylphenyl)carbamic acid	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (29 %)	NA	26190463
DrugRepV_4915	2-[2-(1H-1,3-benzodiazol-1-yl)-N-(4-methanesulfonamidophenyl)acetamido]-N-tert-butyl-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (28 %)	NA	26190463
DrugRepV_4916	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(1H-pyrazol-5-yl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (28 %)	NA	26190463
DrugRepV_4917	N-tert-butyl-2-[1-(4-cyanophenyl)-N-[4-(propan-2-yl)phenyl]formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (28 %)	NA	26190463
DrugRepV_4918	N-tert-butyl-2-{N-[4-(3,5-dimethyl-1,2-oxazol-4-yl)phenyl]-1-(furan-2-yl)formamido}-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (28 %)	NA	26190463
DrugRepV_4919	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(furan-2-yl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (28 %)	NA	26190463
DrugRepV_4920	2-[2-(1H-1,2,3-benzotriazol-1-yl)-N-(4-methanesulfonamidophenyl)acetamido]-N-tert-butyl-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (27 %)	NA	26190463
DrugRepV_4921	N-tert-butyl-2-[N-(4-acetamidophenyl)-2-(1H-1,2,3-triazol-1-yl)acetamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (27 %)	NA	26190463
DrugRepV_4922	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(4-chlorophenyl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (27 %)	NA	26190463
DrugRepV_4923	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(5-methylfuran-2-yl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (26 %)	NA	26190463
DrugRepV_4924	N-tert-butyl-2-[2-(naphthalen-1-yl)-N-[4-(propan-2-yl)phenyl]acetamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (26 %)	NA	26190463
DrugRepV_4925	N-tert-butyl-2-(4-tert-butylphenyl)-2-[N-(4-tert-butylphenyl)-1-(furan-2-yl)formamido]acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (26 %)	NA	26190463
DrugRepV_4926	N-tert-butyl-2-[N-(4-tert-butylphenyl)-2-(naphthalen-1-yl)acetamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (26 %)	NA	26190463
DrugRepV_4927	N-tert-butyl-2-{N-[4-(fluoromethoxy)phenyl]-2-(1H-indol-3-yl)acetamido}-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (25 %)	NA	26190463
DrugRepV_4928	N-tert-butyl-2-{N-[4-(propan-2-yl)phenyl]-1-(5,6,7,8-tetrahydronaphthalen-1-yl)formamido}-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (25 %)	NA	26190463
DrugRepV_4929	N-tert-butyl-2-[2-(1H-indol-3-yl)-N-[4-(propan-2-yl)phenyl]acetamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (25 %)	NA	26190463
DrugRepV_4930	N-tert-butyl-2-[1-(furan-2-yl)-N-[4-(2-methylpropoxy)phenyl]formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (25 %)	NA	26190463
DrugRepV_4931	2-{N-[4-(benzyloxy)phenyl]-1-(furan-2-yl)formamido}-N-tert-butyl-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (25 %)	NA	26190463
DrugRepV_4932	N-tert-butyl-2-{N-[4-(propan-2-yl)phenyl]-2-(pyridin-3-yl)acetamido}-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (24 %)	NA	26190463
DrugRepV_4933	N-tert-butyl-2-[N-(4-fluorophenyl)-2-(pyridin-3-yl)acetamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (24 %)	NA	26190463
DrugRepV_4934	N-tert-butyl-2-[N-(4-tert-butylphenyl)-2-(1H-imidazol-4-yl)acetamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (24 %)	NA	26190463
DrugRepV_4935	N-tert-butyl-2-{N-[4-(difluoromethoxy)phenyl]-1-(1H-indazol-3-yl)formamido}-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (24 %)	NA	26190463
DrugRepV_4936	N-tert-butyl-2-[N-(4-tert-butylphenyl)-2-(pyridin-3-yl)acetamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (23 %)	NA	26190463
DrugRepV_4937	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(1H-indazol-3-yl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (23 %)	NA	26190463
DrugRepV_4938	N-tert-butyl-2-(N-{2,6-difluoro-[1,1-biphenyl]-4-yl}-1-(furan-2-yl)formamido)-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (23 %)	NA	26190463
DrugRepV_4939	N-tert-butyl-2-[N-(4-tert-butylphenyl)-2-methoxyacetamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (23 %)	NA	26190463
DrugRepV_4940	N-tert-butyl-2-[N-(4-tert-butylphenyl)-2-(pyridin-3-yl)acetamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (23 %)	NA	26190463
DrugRepV_4941	N-tert-butyl-2-[1-(4-cyanophenyl)-N-cyclopropylformamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (23 %)	NA	26190463
DrugRepV_4942	N-tert-butyl-2-[N-(4-fluorophenyl)-1-(5,6,7,8-tetrahydronaphthalen-1-yl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (22 %)	NA	26190463
DrugRepV_4943	N-tert-butyl-2-[N-cyclopropyl-2-(naphthalen-1-yl)acetamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (22 %)	NA	26190463
DrugRepV_4944	N-tert-butyl-2-[N-(4-fluorophenyl)-2-(naphthalen-1-yl)acetamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (22 %)	NA	26190463
DrugRepV_4945	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(1H-imidazol-2-yl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (22 %)	NA	26190463
DrugRepV_4946	2-(N-{[1,1-biphenyl]-4-yl}-1-(furan-2-yl)formamido)-N-tert-butyl-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (22 %)	NA	26190463
DrugRepV_4947	N-tert-butyl-2-[N-(4-fluorophenyl)-2-(1H-indol-3-yl)acetamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (22 %)	NA	26190463
DrugRepV_4948	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(5,6,7,8-tetrahydronaphthalen-1-yl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (21 %)	NA	26190463
DrugRepV_4949	N-tert-butyl-2-[N-cyclopropyl-1-(1H-indazol-3-yl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (21 %)	NA	26190463
DrugRepV_4950	N-tert-butyl-2-{N-[4-(fluoromethoxy)phenyl]-2-(naphthalen-1-yl)acetamido}-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (21 %)	NA	26190463
DrugRepV_4951	N-tert-butyl-2-[N-(4-tert-butylphenyl)-2-(4-fluorophenyl)acetamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (21 %)	NA	26190463
DrugRepV_4952	N-tert-butyl-2-[1-(1H-indazol-3-yl)-N-[4-(propan-2-yl)phenyl]formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (21 %)	NA	26190463
DrugRepV_4953	N-tert-butyl-2-[1-(4-cyanophenyl)-N-[4-(propan-2-yl)phenyl]formamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (21 %)	NA	26190463
DrugRepV_4954	N-tert-butyl-2-[N-cyclopropyl-1-(1H-indazol-3-yl)formamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (21 %)	NA	26190463
DrugRepV_4955	N-tert-butyl-2-[1-(furan-2-yl)-N-{4-[(1E)-2-phenylethenyl]phenyl}formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (21 %)	NA	26190463
DrugRepV_4956	N-tert-butyl-2-{N-[4-(fluoromethoxy)phenyl]-1-(5,6,7,8-tetrahydronaphthalen-2-yl)formamido}-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (21 %)	NA	26190463
DrugRepV_4957	(2R)-2-{N-[4-(butan-2-yl)phenyl]-1-(furan-2-yl)formamido}-N-tert-butyl-2-(pyridin-4-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (20 %)	NA	26190463
DrugRepV_4958	N-tert-butyl-2-[N-(4-acetamidophenyl)-2-[4-(trimethylsilyl)-1H-1,2,3-triazol-1-yl]acetamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (20 %)	NA	26190463
DrugRepV_4959	2-{N-[4-(butan-2-yloxy)phenyl]-1-(furan-2-yl)formamido}-N-tert-butyl-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (20 %)	NA	26190463
DrugRepV_4960	N-tert-butyl-2-[1-(4-cyanophenyl)-N-cyclopropylformamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (20 %)	NA	26190463
DrugRepV_4961	N-tert-butyl-2-[N-(4-tert-butylphenyl)-2-phenylacetamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (20 %)	NA	26190463
DrugRepV_4962	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(furan-2-yl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (20 %)	NA	26190463
DrugRepV_4963	N-tert-butyl-2-{N-[4-(propan-2-yl)phenyl]-1-(5,6,7,8-tetrahydronaphthalen-1-yl)formamido}-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (20 %)	NA	26190463
DrugRepV_4964	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(furan-2-yl)formamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (19 %)	NA	26190463
DrugRepV_4965	2-[1-(1-benzofuran-3-yl)-N-(4-tert-butylphenyl)formamido]-N-tert-butyl-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (19 %)	NA	26190463
DrugRepV_4966	N-tert-butyl-2-[N-(4-acetamidophenyl)-2-(4-phenyl-1H-1,2,3-triazol-1-yl)acetamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (19 %)	NA	26190463
DrugRepV_4967	N-tert-butyl-2-[N-(4-fluorophenyl)-1-[5-(trifluoromethyl)pyridin-2-yl]formamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (19 %)	NA	26190463
DrugRepV_4968	N-tert-butyl-2-[N-(4-tert-butylphenyl)-2-(2-methyl-1H-1,3-benzodiazol-1-yl)acetamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (19 %)	NA	26190463
DrugRepV_4969	N-tert-butyl-2-[1-(furan-2-yl)-N-(4-phenoxyphenyl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (19 %)	NA	26190463
DrugRepV_4970	2-methylpropyl N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(tert-butylcarbamoyl)(thiophen-3-yl)methyl]acetamido]phenyl}carbamate	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (19 %)	NA	26190463
DrugRepV_4971	N-(4-{N-[(tert-butylcarbamoyl)(thiophen-3-yl)methyl]-2-(2-methyl-1H-imidazol-1-yl)acetamido}phenyl)propanamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (19 %)	NA	26190463
DrugRepV_4972	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(oxolan-2-yl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (18 %)	NA	26190463
DrugRepV_4973	N-tert-butyl-2-[N-cyclopropyl-1-(5,6,7,8-tetrahydronaphthalen-1-yl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (18 %)	NA	26190463
DrugRepV_4974	2-[N-(4-aminophenyl)-2-(1H-1,3-benzodiazol-1-yl)acetamido]-N-tert-butyl-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (18 %)	NA	26190463
DrugRepV_4975	N-tert-butyl-2-(N-{2,3-difluoro-[1,1-biphenyl]-4-yl}-1-(furan-2-yl)formamido)-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (18 %)	NA	26190463
DrugRepV_4976	N-tert-butyl-2-{N-[4-(fluoromethoxy)phenyl]-1-[5-(trifluoromethyl)pyridin-2-yl]formamido}-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (18 %)	NA	26190463
DrugRepV_4977	N-tert-butyl-2-[1-(furan-2-yl)-N-[4-(propan-2-yl)phenyl]formamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (18 %)	NA	26190463
DrugRepV_4978	N-tert-butyl-2-[N-cyclopropyl-1-(furan-2-yl)formamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (18 %)	NA	26190463
DrugRepV_4979	N-tert-butyl-2-[1-(furan-2-yl)-N-[4-(3-methoxyphenoxy)phenyl]formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (18 %)	NA	26190463
DrugRepV_4980	N-(4-{N-[(tert-butylcarbamoyl)(thiophen-3-yl)methyl]-2-(2-methyl-1H-imidazol-1-yl)acetamido}phenyl)-2-methylpropanamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (18 %)	NA	26190463
DrugRepV_4981	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(1H-pyrrol-2-yl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (18 %)	NA	26190463
DrugRepV_4982	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(4-cyanophenyl)formamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (18 %)	NA	26190463
DrugRepV_4983	N-tert-butyl-2-{N-[4-(propan-2-yl)phenyl]-1-[6-(trifluoromethyl)pyridin-3-yl]formamido}-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (18 %)	NA	26190463
DrugRepV_4984	N-tert-butyl-2-{N-[4-(fluoromethoxy)phenyl]-2-(pyridin-3-yl)acetamido}-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (18 %)	NA	26190463
DrugRepV_4985	2-[N-(adamantan-1-yl)-1-(furan-2-yl)formamido]-N-tert-butyl-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (18 %)	NA	26190463
DrugRepV_4986	N-tert-butyl-2-[N-(4-fluorophenyl)-1-(5,6,7,8-tetrahydronaphthalen-1-yl)formamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (17 %)	NA	26190463
DrugRepV_4987	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(1H-pyrazol-3-yl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (17 %)	NA	26190463
DrugRepV_4988	N-tert-butyl-2-[N-(4-acetamidophenyl)-2-(2-methyl-1H-imidazol-1-yl)acetamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (17 %)	NA	26190463
DrugRepV_4989	tert-butyl 2-(4-{N-[(tert-butylcarbamoyl)(pyridin-3-yl)methyl]furan-2-amido}phenyl)-1H-pyrrole-1-carboxylate	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (17 %)	NA	26190463
DrugRepV_4990	N-tert-butyl-2-{N-[4-(difluoromethoxy)phenyl]-1-(1H-indazol-3-yl)formamido}-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (17 %)	NA	26190463
DrugRepV_4991	N-tert-butyl-2-[N-cyclopropyl-2-(1H-indol-3-yl)acetamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (17 %)	NA	26190463
DrugRepV_4992	2-[N-(4-aminophenyl)-2-(2-methyl-1H-imidazol-1-yl)acetamido]-N-tert-butyl-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (17 %)	NA	26190463
DrugRepV_4993	N-tert-butyl-2-{N-[4-(fluoromethoxy)phenyl]-2-(naphthalen-1-yl)acetamido}-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (17 %)	NA	26190463
DrugRepV_4994	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-[6-(trifluoromethyl)pyridin-3-yl]formamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (17 %)	NA	26190463
DrugRepV_4995	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(3-methoxyphenyl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (17 %)	NA	26190463
DrugRepV_4996	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(2-methoxyphenyl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (17 %)	NA	26190463
DrugRepV_4997	N-tert-butyl-2-(N-{3-cyano-[1,1-biphenyl]-4-yl}-1-(furan-2-yl)formamido)-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (16 %)	NA	26190463
DrugRepV_4998	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(furan-2-yl)formamido]-2-(pyrimidin-5-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (16 %)	NA	26190463
DrugRepV_4999	N-tert-butyl-2-[N-(4-fluorophenyl)-1-(furan-2-yl)formamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (16 %)	NA	26190463
DrugRepV_5000	2-[N-(adamantan-1-yl)-2-(1H-1,2,3-benzotriazol-1-yl)acetamido]-N-benzyl-2-(3-fluorophenyl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (16 %)	NA	26190463
DrugRepV_5001	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(thiophen-3-yl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (16 %)	NA	26190463
DrugRepV_5002	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-[5-(trifluoromethyl)furan-2-yl]formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (16 %)	NA	26190463
DrugRepV_5003	N-tert-butyl-2-[N-cyclopropyl-2-(pyridin-3-yl)acetamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (16 %)	NA	26190463
DrugRepV_5004	N-tert-butyl-2-[1-(4-cyanophenyl)-N-[4-(fluoromethoxy)phenyl]formamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (16 %)	NA	26190463
DrugRepV_5005	N-tert-butyl-2-(N-{2,4-difluoro-[1,1-biphenyl]-4-yl}-1-(furan-2-yl)formamido)-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (16 %)	NA	26190463
DrugRepV_5006	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(1H-indazol-3-yl)formamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (16 %)	NA	26190463
DrugRepV_5007	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(1H-pyrrol-2-yl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (16 %)	NA	26190463
DrugRepV_5008	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(4-methoxyphenyl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (16 %)	NA	26190463
DrugRepV_5009	2-[N-(4-benzenesulfonamidophenyl)-1-(furan-2-yl)formamido]-N-tert-butyl-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (16 %)	NA	26190463
DrugRepV_5010	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(furan-2-yl)formamido]-2-(1H-1,2,3-triazol-4-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (16 %)	NA	26190463
DrugRepV_5011	2-(N-{bicyclo[2.2.1]heptan-2-yl}-1-(furan-2-yl)formamido)-N-tert-butyl-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (16 %)	NA	26190463
DrugRepV_5012	N-tert-butyl-2-{N-[4-(2-fluoropyridin-4-yl)phenyl]-1-(furan-2-yl)formamido}-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (16 %)	NA	26190463
DrugRepV_5013	2-[2-(1H-1,2,3-benzotriazol-1-yl)-N-{bicyclo[2.2.1]heptan-2-yl}acetamido]-N-tert-butyl-2-(3-fluorophenyl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (15 %)	NA	26190463
DrugRepV_5014	N-tert-butyl-2-[1-(furan-2-yl)-N-[4-(pyridin-3-yl)phenyl]formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (15 %)	NA	26190463
DrugRepV_5015	2-[2-(1H-1,3-benzodiazol-1-yl)-N-(4-tert-butylphenyl)acetamido]-N-tert-butyl-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (15 %)	NA	26190463
DrugRepV_5016	N-tert-butyl-2-[N-(4-tert-butylphenyl)-2-(naphthalen-1-yl)acetamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (15 %)	NA	26190463
DrugRepV_5017	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-[6-(trifluoromethyl)pyridin-3-yl]formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (15 %)	NA	26190463
DrugRepV_5018	N-tert-butyl-2-{N-[4-(fluoromethoxy)phenyl]-1-(5,6,7,8-tetrahydronaphthalen-1-yl)formamido}-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (15 %)	NA	26190463
DrugRepV_5019	N-tert-butyl-2-{N-[4-(propan-2-yl)phenyl]-1-[6-(trifluoromethyl)pyridin-3-yl]formamido}-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (15 %)	NA	26190463
DrugRepV_5020	N-tert-butyl-2-{N-[4-(fluoromethoxy)phenyl]-1-[6-(trifluoromethyl)pyridin-3-yl]formamido}-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (15 %)	NA	26190463
DrugRepV_5021	N-tert-butyl-2-[1-(4-cyanophenyl)-N-[4-(fluoromethoxy)phenyl]formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (15 %)	NA	26190463
DrugRepV_5022	N-tert-butyl-2-[N-(4-fluorophenyl)-2-(naphthalen-1-yl)acetamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (15 %)	NA	26190463
DrugRepV_5023	N-tert-butyl-2-[N-(4-tert-butylphenyl)-2-(5,6,7,8-tetrahydronaphthalen-1-yl)acetamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (14 %)	NA	26190463
DrugRepV_5024	N-tert-butyl-2-[N-(4-fluorophenyl)-1-(1H-indazol-3-yl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (14 %)	NA	26190463
DrugRepV_5025	N-tert-butyl-2-(N-{4-cyano-[1,1-biphenyl]-4-yl}-1-(furan-2-yl)formamido)-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (14 %)	NA	26190463
DrugRepV_5026	N-(4-{N-[(tert-butylcarbamoyl)(thiophen-3-yl)methyl]-2-(2-methyl-1H-1,3-benzodiazol-1-yl)acetamido}phenyl)-2-methylpropanamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (14 %)	NA	26190463
DrugRepV_5027	2-[N-(adamantan-1-yl)-2-(1H-1,2,3-benzotriazol-1-yl)acetamido]-N-tert-butyl-2-(3-fluorophenyl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (14 %)	NA	26190463
DrugRepV_5028	2-[2-(1H-1,3-benzodiazol-1-yl)-N-(4-acetamidophenyl)acetamido]-N-tert-butyl-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (14 %)	NA	26190463
DrugRepV_5029	2-{N-[4-(benzyloxy)phenyl]-1-(furan-2-yl)formamido}-N-tert-butyl-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (14 %)	NA	26190463
DrugRepV_5030	N-tert-butyl-2-[N-cyclopropyl-1-(5,6,7,8-tetrahydronaphthalen-1-yl)formamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (14 %)	NA	26190463
DrugRepV_5031	N-tert-butyl-2-[1-(furan-2-yl)-N-[4-(pyrimidin-5-yl)phenyl]formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (14 %)	NA	26190463
DrugRepV_5032	2-[N-(4-aminophenyl)-2-(2-methyl-1H-1,3-benzodiazol-1-yl)acetamido]-N-tert-butyl-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (14 %)	NA	26190463
DrugRepV_5033	N-tert-butyl-2-{N-[4-(difluoromethoxy)phenyl]-1-(furan-2-yl)formamido}-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (13 %)	NA	26190463
DrugRepV_5034	N-tert-butyl-2-[N-(4-methanesulfonamidophenyl)-2-(2-methyl-1H-imidazol-1-yl)acetamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (13 %)	NA	26190463
DrugRepV_5035	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(pyrimidin-2-yl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (13 %)	NA	26190463
DrugRepV_5036	N-tert-butyl-2-[2-(naphthalen-1-yl)-N-[4-(propan-2-yl)phenyl]acetamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (13 %)	NA	26190463
DrugRepV_5037	N-tert-butyl-2-[1-(furan-2-yl)-N-[4-(propan-2-yloxy)phenyl]formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (13 %)	NA	26190463
DrugRepV_5038	N-tert-butyl-2-[1-(4-cyanophenyl)-N-(4-fluorophenyl)formamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (13 %)	NA	26190463
DrugRepV_5039	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(pyridin-3-yl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (13 %)	NA	26190463
DrugRepV_5040	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(pyridin-4-yl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (13 %)	NA	26190463
DrugRepV_5041	N-[(tert-butylcarbamoyl)(pyridin-3-yl)methyl]-N-(4-tert-butylphenyl)-3,3,3-trifluoropropanamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (13 %)	NA	26190463
DrugRepV_5042	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(5-chlorofuran-2-yl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (12 %)	NA	26190463
DrugRepV_5043	N-tert-butyl-2-{N-cyclopropyl-1-[6-(trifluoromethyl)pyridin-3-yl]formamido}-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (12 %)	NA	26190463
DrugRepV_5044	N-tert-butyl-2-[N-(4-ethoxyphenyl)-1-(furan-2-yl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (12 %)	NA	26190463
DrugRepV_5045	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(furan-2-yl)formamido]-2-(1H-pyrazol-4-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (12 %)	NA	26190463
DrugRepV_5046	2-[2-(1H-1,2,3-benzotriazol-1-yl)-N-{bicyclo[2.2.1]heptan-2-yl}acetamido]-N-benzyl-2-(3-fluorophenyl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (12 %)	NA	26190463
DrugRepV_5047	N-tert-butyl-2-(N-{3,4-difluoro-[1,1-biphenyl]-4-yl}-1-(furan-2-yl)formamido)-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (12 %)	NA	26190463
DrugRepV_5048	N-tert-butyl-2-[1-(furan-2-yl)-N-(4-methanesulfonamidophenyl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (12 %)	NA	26190463
DrugRepV_5049	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(pyridin-3-yl)formamido]-2-(pyridin-2-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (12 %)	NA	26190463
DrugRepV_5050	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(4-hydroxyphenyl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (11 %)	NA	26190463
DrugRepV_5051	N-tert-butyl-2-[N-(4-fluorophenyl)-1-(1H-indazol-3-yl)formamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (11 %)	NA	26190463
DrugRepV_5052	N-tert-butyl-2-[N-(4-tert-butylphenyl)-2-(2-methyl-1H-imidazol-1-yl)acetamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (11 %)	NA	26190463
DrugRepV_5053	N-tert-butyl-2-[N-cyclopropyl-2-(naphthalen-1-yl)acetamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (11 %)	NA	26190463
DrugRepV_5054	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(furan-2-yl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (11 %)	NA	26190463
DrugRepV_5055	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(4-cyanophenyl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (11 %)	NA	26190463
DrugRepV_5056	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(2-hydroxyphenyl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (11 %)	NA	26190463
DrugRepV_5057	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(furan-2-yl)formamido]-2-(1H-pyrazol-5-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (11 %)	NA	26190463
DrugRepV_5058	N-tert-butyl-2-[1-(1H-indazol-3-yl)-N-[4-(propan-2-yl)phenyl]formamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (11 %)	NA	26190463
DrugRepV_5059	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(3-hydroxyphenyl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (10 %)	NA	26190463
DrugRepV_5060	N-tert-butyl-2-[1-(furan-2-yl)-N-(4-propoxyphenyl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (10 %)	NA	26190463
DrugRepV_5061	N-tert-butyl-2-[1-(furan-2-yl)-N-(4-methoxyphenyl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (10 %)	NA	26190463
DrugRepV_5062	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(furan-2-yl)formamido]-2-(1H-imidazol-4-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (9 %)	NA	26190463
DrugRepV_5063	2-[2-(1H-1,2,3-benzotriazol-1-yl)-N-(4-tert-butylphenyl)acetamido]-N-tert-butyl-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (9 %)	NA	26190463
DrugRepV_5064	2-[N-(4-benzylphenyl)-1-(furan-2-yl)formamido]-N-tert-butyl-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (8 %)	NA	26190463
DrugRepV_5065	N-(4-{N-[(tert-butylcarbamoyl)(thiophen-3-yl)methyl]-2-(2-methyl-1H-1,3-benzodiazol-1-yl)acetamido}phenyl)propanamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (8 %)	NA	26190463
DrugRepV_5066	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(furan-2-yl)formamido]-2-(6-methylpyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (8 %)	NA	26190463
DrugRepV_5067	N-tert-butyl-2-[N-cyclohexyl-1-(furan-2-yl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (6 %)	NA	26190463
DrugRepV_5072	Favipiravir	Antiviral	Influenza virus	Crimean-Congo hemorrhagic fever virus	10200	NA	NA	Decrease (50 %)	Investigational	29936152
DrugRepV_5073	Favipiravir	Antiviral	Influenza virus	Crimean-Congo hemorrhagic fever virus	Hoti	NA	NA	Decrease (50 %)	Investigational	29936152
DrugRepV_5253	beta-D-cyclopentenyl cytosine	NA	NA	Variola virus	Bangladesh 1975	NA	NA	Decrease (50 %)	NA	14604375
DrugRepV_5254	beta-D-cyclopentenyl cytosine	NA	NA	Variola virus	7124	NA	NA	Decrease (50 %)	NA	14604375
DrugRepV_5255	beta-D-cyclopentenyl-5-iodocytidine	NA	NA	Variola virus	Bangladesh 1975	NA	NA	Decrease (50 %)	NA	14604375
DrugRepV_5256	beta-D-cyclopentenyl-5-iodocytidine	NA	NA	Variola virus	7124	NA	NA	Decrease (50 %)	NA	14604375
DrugRepV_5257	beta-D-Cyclopentenyl-5-chlorocytidine	NA	NA	Variola virus	Bangladesh 1975	NA	NA	Decrease (50 %)	NA	14604375
DrugRepV_5258	beta-D-Cyclopentenyl-5-chlorocytidine	NA	NA	Variola virus	7124	NA	NA	Decrease (50 %)	NA	14604375
DrugRepV_5259	beta-D-cyclopentenyl-5-bromocytidine	NA	NA	Variola virus	Bangladesh 1975	NA	NA	Decrease (50 %)	NA	14604375
DrugRepV_5260	beta-D-cyclopentenyl-5-bromocytidine	NA	NA	Variola virus	7124	NA	NA	Decrease (50 %)	NA	14604375
DrugRepV_5387	Quinacrine	NA	Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions	Chikungunya virus	NA	NA	NA	Decrease (50 %)	Investigational	31307979
DrugRepV_5388	Quinacrine	NA	Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions	Ebola virus	NA	NA	NA	Decrease (50 %)	Investigational	31307979
DrugRepV_5389	Quinacrine	NA	Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions	Influenza virus	NA		NA	Decrease (50 %)	Investigational	31307979
DrugRepV_5390	Quinacrine	NA	Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	Investigational	31307979
DrugRepV_5391	Quinacrine	NA	Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions	Rift Valley fever virus	NA	NA	NA	Decrease (50 %)	Investigational	31307979
DrugRepV_5392	Quinacrine	NA	Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions	Zika virus	NA	NA	NA	Decrease (50 %)	Investigational	31307979
DrugRepV_5422	Losmapimod	NA	Chronic Obstructive Pulmonary Disease	Lassa virus	LP	NA	NA	Decrease (50 %)	Investigational	30953674
DrugRepV_5423	Losmapimod	NA	Chronic Obstructive Pulmonary Disease	Lassa virus	803213	NA	NA	Decrease (50 %)	Investigational	30953674
DrugRepV_5424	Losmapimod	NA	Chronic Obstructive Pulmonary Disease	Lassa virus	GA391	NA	NA	Decrease (50 %)	Investigational	30953674
DrugRepV_5425	Losmapimod	NA	Chronic Obstructive Pulmonary Disease	Lassa virus	Josiah	NA	NA	Decrease (50 %)	Investigational	30953674
DrugRepV_5426	ST-193	NA	NA	Lassa virus	LP	NA	NA	Decrease (50 %)	NA	30953674
DrugRepV_5427	ST-193	NA	NA	Lassa virus	803213	NA	NA	Decrease (50 %)	NA	30953674
DrugRepV_5428	ST-193	NA	NA	Lassa virus	GA391	NA	NA	Decrease (50 %)	NA	30953674
DrugRepV_5429	ST-193	NA	NA	Lassa virus	Josiah	NA	NA	Decrease (50 %)	NA	30953674
DrugRepV_5531	JQ1	NA	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	NA	32353859
DrugRepV_5532	RVX-208	NA	Diabetes, Atherosclerosis, and Coronary Artery Disease	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	NA	32353859
DrugRepV_5533	Silmitasertib	NA	Medulloblastoma	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	Investigational	32353859
DrugRepV_5534	TMCB	NA	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	NA	32353859
DrugRepV_5535	Apicidin	NA	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	NA	32353859
DrugRepV_5536	Valproic Acid	Nervous System	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	Approved, Investigational	32353859
DrugRepV_5537	Bafilomycin A1	Antibiotics	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	Experimental	32353859
DrugRepV_5538	E-52862	NA	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	NA	32353859
DrugRepV_5539	PD-144418	NA	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	NA	32353859
DrugRepV_5540	RS-PPCC	NA	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	NA	32353859
DrugRepV_5541	PB28	NA	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	NA	32353859
DrugRepV_5542	Haloperidol	Nervous System	Schizophrenia | Psychotic disorders | Chemotherapy-induced nausea/vomiting	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	Approved	32353859
DrugRepV_5543	Entacapone	Nervous System	Parkinson Disease	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	Approved	32353859
DrugRepV_5544	Indomethacin	Cardiovascular agents; Musculo-Skeletal System; Musculo-Skeletal System	Rheumatoid arthritis | Ankylosing spondylitis | Osteoarthritis | Acute painful shoulder (bursitis and/or tendinitis) | Acute gouty arthritis	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	Approved, Investigational	32353859
DrugRepV_5545	Metformin	Alimentary Tract and Metabolism	Diabetes	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	Approved	32353859
DrugRepV_5546	Ponatinib	Antineoplastic and Immunomodulating Agentss	Chronic myeloid leukemia	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	Approved, Investigational	32353859
DrugRepV_5547	H-89	NA	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	NA	32353859
DrugRepV_5548	Merimepodib	NA	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	Investigational	32353859
DrugRepV_5549	Migalastat	Alimentary Tract and Metabolism	Fabry disease	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	Approved, Investigational	32353859
DrugRepV_5550	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	Approved	32353859
DrugRepV_5551	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	Approved	32353859
DrugRepV_5552	XL413	NA	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	NA	32353859
DrugRepV_5553	CCT 365623	NA	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	NA	32353859
DrugRepV_5554	Midostaurin	Antineoplastic and Immunomodulating Agentss	Acute myeloid leukemia (AML)	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	Approved, Investigational	32353859
DrugRepV_5555	Ruxolitinib	Antineoplastic and Immunomodulating Agentss	Bone marrow cancer	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	Approved	32353859
DrugRepV_5556	ZINC1775962367	NA	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	NA	32353859
DrugRepV_5557	ZINC4326719	NA	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	NA	32353859
DrugRepV_5558	ZINC4511851	NA	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	NA	32353859
DrugRepV_5559	ZINC95559591	NA	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	NA	32353859
DrugRepV_5560	AC-55541	NA	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	NA	32353859
DrugRepV_5561	AZ8838	NA	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	NA	32353859
DrugRepV_5562	Daunorubicin	Antineoplastic and Immunomodulating Agentss	Cancer	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	Approved	32353859
DrugRepV_5563	GB110	NA	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	NA	32353859
DrugRepV_5564	S-verapamil	NA	Hypertension (high blood pressure) | Angina (chest pain) | Arrhythmia (heart rhythm disorders).	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	Approved	32353859
DrugRepV_5565	AZ3451	NA	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	NA	32353859
DrugRepV_5566	ABBV-744	NA	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	NA	32353859
DrugRepV_5567	dBET6	NA	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	NA	32353859
DrugRepV_5568	MZ1	NA	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	NA	32353859
DrugRepV_5569	CPI-0610	NA	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	NA	32353859
DrugRepV_5570	Sapanisertib	NA	Tumor	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	Investigational	32353859
DrugRepV_5571	Rapamycin	Antineoplastic and Immunomodulating Agents; Sensory Organ	Prophylaxis of organ rejection in patients receiving renal transplants	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	Approved, Investigational	32353859
DrugRepV_5572	Zotatifin	NA	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	NA	32353859
DrugRepV_5573	Verdinexor	NA	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	Investigational	32353859
DrugRepV_5574	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	Approved	32353859
DrugRepV_5575	Dabrafenib	Antineoplastic and Immunomodulating Agents	Melanoma	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	Approved	32353859
DrugRepV_5576	WDB002	NA	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	NA	32353859
DrugRepV_5577	Sanglifehrin A	NA	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	Experimental	32353859
DrugRepV_5578	FK-506	Dermatologicals; Antineoplastic and Immunomodulating Agents	Liver transplantation	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	Approved	32353859
DrugRepV_5579	Pevonedistat	NA	Lymphoma	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	Investigational	32353859
DrugRepV_5580	Ternatin 4	NA	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	NA	32353859
DrugRepV_5581	4E2RCat	NA	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	NA	32353859
DrugRepV_5582	Tomivosertib	NA	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	Investigational	32353859
DrugRepV_5583	(2R,5S,11S,14S,17R,18R,21E)-2-(2-aminoethyl)-18-methoxy-11,17-dimethyl-14-(propan-2-yl)-3-oxa-9,12,15,28-tetraazatricyclo[21.3.1.1?,?]octacosa-1(26),21,23(27),24-tetraene-4,10,13,16-tetrone	NA	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	NA	32353859
DrugRepV_5584	N-(5-{3-[(4-Hydroxyphenyl)sulfamoyl]-4-methoxyphenyl}-4-methyl-1,3-thiazol-2-yl)-2,2-dimethylpropanamide	NA	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	NA	32353859
DrugRepV_5585	PS3061	NA	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	NA	32353859
DrugRepV_5586	IHVR-19029	NA	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	NA	32353859
DrugRepV_5587	Captopril	Cardiovascular agents	Hypertension	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	Approved	32353859
DrugRepV_5588	Lisinopril	Cardiovascular agents	Hypertension | Congestive heart failure	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	Approved, Investigational	32353859
DrugRepV_5589	Camostat	Blood and Blood Forming Organs	Pancreatitis	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	Experimental	32353859
DrugRepV_5590	Nafamostat	NA	Blood vessel coagulation | Hemorrhagic lesions	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	Investigational	32353859
DrugRepV_5591	Chloramphenicol	Antiinfectives For Systemic Use	Bacterial infections	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	Approved	32353859
DrugRepV_5592	Tigecycline	Antiinfectives For Systemic Use	Complicated skin and skin structure infections	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	Approved	32353859
DrugRepV_5593	Linezolid	Antiinfectives For Systemic Use	Bacterial infections	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	Approved, Investigational	32353859
DrugRepV_5604	Sunitinib-Erlotinib	NA	NA	Dengue virus	N124D/K128E		NA	Increase	NA	28240606
DrugRepV_5648	Celgosivir	Antiviral	Hepatitis C virus	Dengue virus	DENV1-2402		NA	Increase	Phase II	26794905
DrugRepV_5649	Celgosivir	Antiviral	Hepatitis C virus	Dengue virus	DENV2-3295		NA	Increase	Phase II	26794905
DrugRepV_5650	Celgosivir	Antiviral	Hepatitis C virus	Dengue virus	S221		NA	Increase	Phase II	26794905
DrugRepV_6064	N2-(4-fluorophenyl)-N3-(4-methyl-2-(3-methyl-1H-pyrazol- 5-yl)phenyl) pyrazine-2,3 dicarboxamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6065	N2-(4-methyl-2-(3-methyl-1H-pyrazol-5-yl)phenyl)-N3-(p- tolyl)pyrazine-2,3-dicarboxamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6066	N2-(4-fluorophenyl)-N3-(4-methyl-2-(thiophen-2-yl)phenyl) pyrazine-2,3-dicarboxamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6067	N2-(4-methyl-2-(thiophen-2-yl)phenyl)-N3-(p-tolyl) pyrazine-2,3-dicarboxamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6068	N2-(4-fluorophenyl)-N3-(4-methyl-2-(5-methylthiophen-2-yl)phenyl)pyrazine-2,3-dicarboxamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6069	N2-(4-methyl-2-(5-methylthiophen-2-yl)phenyl)-N3-(p- tolyl)pyrazine-2,3-dicarboxamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6070	N2-(4-fluorophenyl)-N3-(4-methyl-2-(thiophen-3-yl) phenyl)pyrazine-2,3- dicarboxamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6071	N2-(4-methyl-2-(thiophen-3-yl)phenyl)-N3-(p-tolyl) pyrazine-2,3-dicarboxamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6072	N2-(4-fluorophenyl)-N3-(2-(thiophen-3-yl)benzyl)pyrazine- 2,3-dicarboxamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6073	N2-(2-(thiophen-3-yl)benzyl)-N3-(p-tolyl)pyrazine-2,3-dicarboxamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6074	N2-(4-fluorophenyl)-N3-(4-(thiophen-3-yl)benzyl)pyrazine-2,3-dicarboxamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6075	N2-(4-(thiophen-3-yl)benzyl)-N3-(p-tolyl)pyrazine-2,3-dicarboxamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6076	N2-(4-fluorophenyl)-N3-(2-(3-methyl-1H-pyrazol-5-yl) phenyl)pyrazine-2,3-dicarboxamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6077	N2-(2-(3-methyl-1H-pyrazol-5-yl)phenyl)-N3-(p-tolyl) pyrazine-2,3-di-carboxamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6078	N1-(4-fluorophenyl)-N2-(4-methyl-2-(3-methyl-1H-pyrazol-5-yl)phenyl)phthalamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6079	N1-(4-fluorophenyl)-N2-(4-methyl-2-(thiophen-2-yl) phenyl)phthalamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6080	N1-(4-methyl-2-(3-methyl-1H-pyrazol-5-yl)phenyl)-N2-(p- tolyl)phthalamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6081	N1-(4-methyl-2-(thiophen-2-yl)phenyl)-N2-(p-tolyl)phthalamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6082	N1-(4-methyl-2-(5-methylthiophen-2-yl)phenyl)-N2-(p- tolyl)phthalamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6083	N1-(4-fluorophenyl)-N2-(4-methyl-2-(5-methylthiophen-2- yl)phenyl)phthalamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6084	N1-(4-methyl-2-(thiophen-3-yl)phenyl)-N2-(p-tolyl)phthalamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6085	N1-(4-fluorophenyl)-N2-(4-methyl-2-(thiophen-3-yl) phenyl)phthalamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6086	N1-(4-fluorophenyl)-N2-(2-(thiophen-3-yl)benzyl) phthalamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6087	N1-(2-(thiophen-3-yl)benzyl)-N2-(p-tolyl)phthalamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6088	N1-(4-fluorophenyl)-N2-(4-(thiophen-3-yl)benzyl) phthalamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6089	N1-(4-(thiophen-3-yl)benzyl)-N2-(p-tolyl)phthalamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6090	N1-(4-fluorophenyl)-N2-(2-(3-methyl-1H-pyrazol-5-yl) phenyl)phthalamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6091	N1-(2-(3-methyl-1H-pyrazol-5-yl)phenyl)-N2-(p-tolyl) phthalamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6092	2-(4-fluorobenzamido)-N-(4-methyl-2-(thiophen-3-yl) phenyl)benzamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6093	2-(4-fluorobenzamido)-N-(4-methyl-2-(5-methylthiophen- 2-yl)phenyl)benzamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6094	2-(4-fluorobenzamido)-N-(4-methyl-2-(pyridin-4-yl)phenyl) benzamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6095	2-(4-fluorobenzamido)-N-(4-methyl-2-(pyridin-3-yl)phenyl) benzamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6128	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Dengue virus	New Guinea C		NA	Decrease (50 %)	Approved	29890736
DrugRepV_6129	IFN-alpha	Antiviral	Hepatitis C virus | Leukemia | Melanoma	Dengue virus	New Guinea C		NA	Decrease (50 %)	Investigational	29890736
DrugRepV_6346	AM404	NA	Pain and Fever	Dengue virus	New Guinea C (NGC)		NA	Decrease (50 %)	Phase IV	26856827
DrugRepV_6347	Paracetamol	Nervous System	Fever | Minor aches | Pains	Dengue virus	New Guinea C (NGC)		NA	Decrease (100 %)	Approved	26856827
DrugRepV_6348	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Dengue virus	New Guinea C (NGC)		NA	Decrease (50 %)	Approved	26856827
DrugRepV_6426	Cdt yellow	NA	NA	Dengue virus	NGC		NA	Decrease (50 %)	NA	21723310
DrugRepV_6427	Cdt white	NA	NA	Dengue virus	NGC		NA	Decrease (50 %)	NA	21723310
DrugRepV_6428	Crotoxin	NA	NA	Dengue virus	NGC		NA	Decrease (50 %)	NA	21723310
DrugRepV_6429	Crotapotin	NA	NA	Dengue virus	NGC		NA	Decrease (50 %)	NA	21723310
DrugRepV_6430	Crotamin	NA	NA	Dengue virus	NGC		NA	Decrease (11 %)	NA	21723310
DrugRepV_6431	Convulxin	NA	NA	Dengue virus	NGC		NA	Decrease (5 %)	NA	21723310
DrugRepV_6432	PLA2-IC	NA	NA	Dengue virus	NGC		NA	Decrease (50 %)	NA	21723310
DrugRepV_6433	PLA2-IC	NA	NA	Dengue virus	NGC		NA	Decrease (50 %)	NA	21723310
DrugRepV_6480	Quinacrine	NA	Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions	Dengue virus	NA		NA	Decrease (50 %)	Investigational	31307979
DrugRepV_6958	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Human immunodeficiency virus	NA		NA	Decrease (50 %)	Approved	15200845
DrugRepV_6959	Lamivudine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome | Hepatitis B virus	Human immunodeficiency virus	NA		NA	Decrease (50 %)	Approved	15200845
DrugRepV_6960	Zidovudine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome/AIDS	Human immunodeficiency virus	NA		NA	Decrease (50 %)	Approved	15200845
DrugRepV_6961	Saquinavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	NA		NA	Decrease (50 %)	Approved, Investigational	15200845
DrugRepV_6962	Nelfinavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	NA		NA	Decrease (95 %)	Approved	15200845
DrugRepV_6963	Indinavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	NA		NA	Decrease (50 %)	Approved	15200845
DrugRepV_6964	(1S,2R,3S)-1-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]uracil	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	11689085
DrugRepV_6965	(1S,2R,3S)-1-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]thymine	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	11689085
DrugRepV_6966	(1S,2R,3S)-1-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]-5-fluorouracil	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	11689085
DrugRepV_6967	(1S,2R,3S)-1-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]cytosine	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	11689085
DrugRepV_6968	(1S,2R,3S)-1-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]-5-fluorocytosine	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	11689085
DrugRepV_6969	L-Neplanocin A	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	11689085
DrugRepV_6970	(1S,2R,3S)-9-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl] hypoxanthine	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	11689085
DrugRepV_6971	(1S,2R,3S)-9-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]guanine	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	11689085
DrugRepV_6972	Cyclopentenyl nucleosides	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	11689085
DrugRepV_6973	(1R,2S,3R)-9-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl] hypoxanthine	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	11689085
DrugRepV_6974	(1R,2S,3R)-9-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]guanine	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	11689085
DrugRepV_6975	(1S,2R,3S)-1-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]uracil	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	11689085
DrugRepV_6976	(1R,2S,3R)-1-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]thymine	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	11689085
DrugRepV_6977	(1R,2S,3R)-1-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]-5-fluorouracil	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	11689085
DrugRepV_6978	(1R,2S,3R)-1-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]cytosine	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	11689085
DrugRepV_6979	(1R,2S,3R)-1-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]-5-fluorocytosine	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	11689085
DrugRepV_7173	N2-(4-fluorophenyl)-N3-(4-methyl-2-(thiophen-2-yl)phenyl) pyrazine-2,3-dicarboxamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7174	N2-(4-fluorophenyl)-N3-(4-methyl-2-(thiophen-3-yl) phenyl)pyrazine-2,3- dicarboxamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7175	N2-(4-methyl-2-(thiophen-3-yl)phenyl)-N3-(p-tolyl) pyrazine-2,3-dicarboxamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7176	N2-(4-fluorophenyl)-N3-(2-(thiophen-3-yl)benzyl)pyrazine- 2,3-dicarboxamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7177	N2-(2-(thiophen-3-yl)benzyl)-N3-(p-tolyl)pyrazine-2,3-dicarboxamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7178	N2-(4-fluorophenyl)-N3-(4-(thiophen-3-yl)benzyl)pyrazine-2,3-dicarboxamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7179	N2-(4-(thiophen-3-yl)benzyl)-N3-(p-tolyl)pyrazine-2,3-dicarboxamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7180	N2-(4-fluorophenyl)-N3-(2-(3-methyl-1H-pyrazol-5-yl) phenyl)pyrazine-2,3-dicarboxamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7181	N2-(2-(3-methyl-1H-pyrazol-5-yl)phenyl)-N3-(p-tolyl) pyrazine-2,3-di-carboxamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7182	N1-(4-fluorophenyl)-N2-(4-methyl-2-(3-methyl-1H-pyrazol-5-yl)phenyl)phthalamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7183	N1-(4-fluorophenyl)-N2-(4-methyl-2-(thiophen-2-yl) phenyl)phthalamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7184	N1-(4-methyl-2-(3-methyl-1H-pyrazol-5-yl)phenyl)-N2-(p- tolyl)phthalamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7185	N1-(4-methyl-2-(thiophen-2-yl)phenyl)-N2-(p-tolyl)phthalamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7186	N1-(4-methyl-2-(5-methylthiophen-2-yl)phenyl)-N2-(p- tolyl)phthalamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7187	N1-(4-fluorophenyl)-N2-(4-methyl-2-(5-methylthiophen-2- yl)phenyl)phthalamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7188	N1-(4-methyl-2-(thiophen-3-yl)phenyl)-N2-(p-tolyl)phthalamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7189	N1-(4-fluorophenyl)-N2-(4-methyl-2-(thiophen-3-yl) phenyl)phthalamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7190	N1-(4-fluorophenyl)-N2-(2-(thiophen-3-yl)benzyl) phthalamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7191	N1-(2-(thiophen-3-yl)benzyl)-N2-(p-tolyl)phthalamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7192	N1-(4-fluorophenyl)-N2-(4-(thiophen-3-yl)benzyl) phthalamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7193	N1-(4-(thiophen-3-yl)benzyl)-N2-(p-tolyl)phthalamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7194	N1-(4-fluorophenyl)-N2-(2-(3-methyl-1H-pyrazol-5-yl) phenyl)phthalamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7195	N1-(2-(3-methyl-1H-pyrazol-5-yl)phenyl)-N2-(p-tolyl) phthalamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7196	2-(4-fluorobenzamido)-N-(4-methyl-2-(thiophen-3-yl) phenyl)benzamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7197	2-(4-fluorobenzamido)-N-(4-methyl-2-(5-methylthiophen- 2-yl)phenyl)benzamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7198	2-(4-fluorobenzamido)-N-(4-methyl-2-(pyridin-4-yl)phenyl) benzamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7199	2-(4-fluorobenzamido)-N-(4-methyl-2-(pyridin-3-yl)phenyl) benzamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7243	BCX4430	NA	Ebola virus	Yellow fever virus	17D		NA	Decrease (50 %)	Investigational	27095300
DrugRepV_7244	1-[4,5-dihydroxy-3-(hydroxymethyl)cyclopent-2-en-1-yl]-1H-1,2,4-triazole-3-carboxamide	NA	NA	West Nile virus	NA		NA	Decrease (50 %)	NA	16451078
DrugRepV_7245	1-[4,5-dihydroxy-3-(hydroxymethyl)cyclopent-2-en-1-yl]-1H-1,2,4-triazole-3-carboxamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	16451078
DrugRepV_7246	1-[4,5-dihydroxy-3-(hydroxymethyl)cyclopent-2-en-1-yl]-1H-imidazole-4-carboxamide	NA	NA	West Nile virus	NA		NA	Decrease (50 %)	NA	16451078
DrugRepV_7247	1-[4,5-dihydroxy-3-(hydroxymethyl)cyclopent-2-en-1-yl]-1H-imidazole-4-carboxamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	16451078
DrugRepV_7248	1-[4,5-dihydroxy-3-(hydroxymethyl)cyclopent-2-en-1-yl]-1H-1,2,3-triazole-4-carboxamide	NA	NA	West Nile virus	NA		NA	Decrease (50 %)	NA	16451078
DrugRepV_7249	1-[4,5-dihydroxy-3-(hydroxymethyl)cyclopent-2-en-1-yl]-1H-1,2,3-triazole-4-carboxamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	16451078
DrugRepV_7267	Cdt yellow	NA	NA	Yellow fever virus	17D		NA	Decrease (50 %)	NA	21723310
DrugRepV_7268	Cdt white	NA	NA	Yellow fever virus	17D		NA	Decrease (50 %)	NA	21723310
DrugRepV_7269	Crotoxin	NA	NA	Yellow fever virus	17D		NA	Decrease (50 %)	NA	21723310
DrugRepV_7270	Crotapotin	NA	NA	Yellow fever virus	17D		NA	Decrease (43 %)	NA	21723310
DrugRepV_7271	Crotamin	NA	NA	Yellow fever virus	17D		NA	Decrease (20 %)	NA	21723310
DrugRepV_7272	Convulxin	NA	NA	Yellow fever virus	17D		NA	Decrease (22 %)	NA	21723310
DrugRepV_7273	PLA2-IC	NA	NA	Yellow fever virus	17D		NA	Decrease (50 %)	NA	21723310
DrugRepV_7274	PLA2-IC	NA	NA	Yellow fever virus	17D		NA	Decrease (50 %)	NA	21723310
DrugRepV_7514	Quinacrine	NA	Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions	Polio virus	NA		NA	Decrease (50 %)	Investigational	31307979
DrugRepV_7515	Quinacrine	NA	Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions	West Nile virus	NA		NA	Decrease (50 %)	Investigational	31307979
DrugRepV_7516	Quinacrine	NA	Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions	Yellow fever virus	NA		NA	Decrease (50 %)	Investigational	31307979
DrugRepV_7520	beta-D-cyclopentenyl cytosine	NA	NA	Vaccinia virus	Copenhagen		NA	Decrease (50 %)	NA	14604375
DrugRepV_7521	beta-D-cyclopentenyl-5-iodocytidine	NA	NA	Vaccinia virus	Copenhagen		NA	Decrease (50 %)	NA	14604375
DrugRepV_7522	beta-D-Cyclopentenyl-5-chlorocytidine	NA	NA	Vaccinia virus	Copenhagen		NA	Decrease (50 %)	NA	14604375
DrugRepV_7523	beta-D-cyclopentenyl-5-bromocytidine	NA	NA	Vaccinia virus	Copenhagen		NA	Decrease (50 %)	NA	14604375
DrugRepV_7524	Quinacrine	NA	Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions	Vaccinia virus	NA		NA	Decrease (50 %)	Investigational	31307979
DrugRepV_7663	Hydroxychloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	SARS Coronavirus-2		NA	NA	Decrease (50 %)	Approved	32344449
DrugRepV_7678	Amiodarone	Cardiovascular agents	Anginal and Arrhythmia	SARS Coronavirus-2	NA	NA	NA	Decrease (50 %)	Approved, Investigational	32577649
DrugRepV_7679	Bosutinib	Antineoplastic and Immunomodulating Agents	Cancer	SARS Coronavirus-2	NA	NA	NA	Decrease (50 %)	Approved	32577649
DrugRepV_7680	Clofazamine	Antiinfectives For Systemic Use	Lepromatous leprosy	SARS Coronavirus-2	NA	NA	NA	Decrease (50 %)	Approved	32577649
DrugRepV_7681	Domperidone	Alimentary Tract and Metabolism	Dyspepsia, heartburn, epigastric pain	SARS Coronavirus-2		NA	NA	Decrease (50 %)	Approved	32577649
DrugRepV_7682	Entecavir	Antiinfectives For Systemic Use	Hepatitis B virus	SARS Coronavirus-2		NA	NA	Decrease (50 %)	Approved	32577649
DrugRepV_7683	Fedratinib	Antineoplastic And Immunomodulating Agents	Myelofibrosis	SARS Coronavirus-2		NA	NA	Decrease (50 %)	Approved, Investigational	32577649
DrugRepV_7684	Gilteritinib	Antineoplastic And Immunomodulating Agents	Acute myeloid leukemia	SARS Coronavirus-2		NA	NA	Decrease (50 %)	Approved, Investigational	32577649
DrugRepV_7685	Ipratropium bromide	Respiratory System	Asthma | Chronic bronchitis | Emphysema	SARS Coronavirus-2		NA	NA	Decrease (50 %)	Approved, Experimental	32577649
DrugRepV_7686	Lomitapide	Cardiovascular system	Hypercholesterolemia	SARS Coronavirus-2		NA	NA	Decrease (50 %)	Approved, Investigational	32577649
DrugRepV_7687	Metoclopramide	Alimentary Tract and Metabolism	Diabetic gastroparesis	SARS Coronavirus-2		NA	NA	Decrease (50 %)	Approved, Investigational	32577649
DrugRepV_7688	Niclosamide	Antiparasitic products, Insectisides and Repellents	Tapeworm and intestinal fluke infections | Helminthiasis	SARS Coronavirus-2		NA	NA	Decrease (50 %)	Approved	32577649
DrugRepV_7689	Remdesivir	Antiviral	Hepatitis C | Ebola	SARS Coronavirus-2	NA	NA	NA	Decrease (50 %)	Experimental	32577649
DrugRepV_7690	S1RA	NA	NA	SARS Coronavirus-2		NA	NA	Decrease (50 %)	NA	32577649
DrugRepV_7691	Thioguanine	Antineoplastic and Immunomodulating Agents	Acute leukemia	SARS Coronavirus-2		NA	NA	Decrease (50 %)	Approved	32577649
DrugRepV_7692	Verapamil	Cardiovascular agents	Hypertension (high blood pressure) | Angina (chest pain) | Arrhythmia (heart rhythm disorders).	SARS Coronavirus-2		NA	NA	Decrease (50 %)	Approved	32577649
DrugRepV_7693	Z-FA-FMK	NA	NA	SARS Coronavirus-2		NA	NA	Decrease (50 %)	NA	32577649
DrugRepV_7694	Lactoferrin	NA	NA	SARS Coronavirus-2		NA	NA	Decrease (50 %)	NA	32577649
DrugRepV_7695	Nafamostat	NA	Blood vessel coagulation | Hemorrhagic lesions	SARS Coronavirus-2		NA	NA	Decrease (50 %)	Investigational	32532094
DrugRepV_7696	Immunoglobulin F(ab’)2	NA	NA	SARS Coronavirus-2		NA	NA	Decrease (50 %)	NA	32659292
DrugRepV_7697	Unfractionated Heparin	NA	Prophylaxis and Venous thrombosis	SARS Coronavirus-2		NA	NA	Decrease (50 %)	Approved, Investigational	32577638
DrugRepV_7698	UFH-de6S	NA	NA	SARS Coronavirus-2		NA	NA	Decrease (50 %)	NA	32577638
DrugRepV_7699	Enoxaparin	Blood And Blood Forming Organs	Deep vein thrombosis	SARS Coronavirus-2		NA	NA	Decrease (50 %)	Approved	32577638
DrugRepV_7700	Enoxaparin-de6S	NA	NA	SARS Coronavirus-2		NA	NA	Decrease (50 %)	NA	32577638
DrugRepV_7771	Remdesivir	Antiviral	Hepatitis C | Ebola	SARS Coronavirus-2	NA	NA	NA	Decrease (50 %)	Experimental	32687696
DrugRepV_7772	Favipiravir	Antiviral	Influenza virus	SARS Coronavirus-2	NA	NA	NA	Decrease (50 %)	Investigational	32687696
DrugRepV_7773	Galidesivir	NA	Ebolavirus	SARS Coronavirus-2	NA	NA	NA	Decrease (50 %)	Investigational	32687696
DrugRepV_7774	Ritonavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	SARS Coronavirus-2	NA	NA	NA	Decrease (50 %)	Approved, Investigational	32687696
DrugRepV_7775	Camostat mesylate	NA	Pancreatitis	SARS Coronavirus-2	NA	NA	NA	Decrease (50 %)	Experimental	32687696
DrugRepV_7776	Nafamostat Mesylate	NA	Blood vessel coagulation | Hemorrhagic lesions	SARS Coronavirus-2	NA	NA	NA	Decrease (50 %)	Investigational	32687696
DrugRepV_7777	Imatinib	Antineoplastic and Immunomodulating Agents	Leukemia | Myelodysplastic/myeloproliferative disease | Gastrointestinal stromal tumors	SARS Coronavirus-2	NA	NA	NA	Decrease (50 %)	Approved	32687696
DrugRepV_7778	Apilimod	NA	Crohn's disease | Psoriasis | Psoriatic disorders	SARS Coronavirus-2	NA	NA	NA	Decrease (50 %)	Investigational	32687696
DrugRepV_7779	Niclosamide	Antiparasitic products, Insectisides and Repellents	Tapeworm and intestinal fluke infections | Helminthiasis	SARS Coronavirus-2	NA	NA	NA	Decrease (50 %)	Approved	32687696
DrugRepV_7780	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	SARS Coronavirus-2	NA	NA	NA	Decrease (50 %)	Approved	32687696
DrugRepV_7781	Hydroxychloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	SARS Coronavirus-2	NA	NA	NA	Decrease (50 %)	Approved	32687696
DrugRepV_7792	Dehydroabieta-7-one	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	17663539
DrugRepV_7793	Cryptojaponol	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	17663539
DrugRepV_7794	8beta-hydroxyabieta-9(11),13- dien-12-one	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	17663539
DrugRepV_7795	7beta-hydroxydeoxycryptojaponol	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	17663539
DrugRepV_7796	6,7-dehydroroyleanone	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	17663539
DrugRepV_7797	3beta,12-diacetoxyabieta-6,8,11,13- tetraene	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	17663539
DrugRepV_7798	Pinusolidic acid	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	17663539
DrugRepV_7799	Forskolin	NA	Smooth muscle relaxant	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	Experimental, Investigational	17663539
DrugRepV_7800	Cedrane-3beta,12-diol	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	17663539
DrugRepV_7801	alpha-cadinol	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	17663539
DrugRepV_7802	Betulinic acid	NA	Dysplastic Nevus Syndrome	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	Investigational	17663539
DrugRepV_7803	Betulonic acid	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	17663539
DrugRepV_7804	Hinokinin	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	17663539
DrugRepV_7805	Savinin	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	17663539
DrugRepV_7806	Honokiol	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	17663539
DrugRepV_7807	Magnolol	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	17663539
DrugRepV_7808	Curcumin	NA	Depressive disorder	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	Approved	17663539
DrugRepV_7809	Niclosamide	Antiparasitic products, Insectisides and Repellents	Tapeworm and intestinal fluke infections | Helminthiasis	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	Approved	17663539
DrugRepV_7810	Valinomycin	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	Experimental	17663539
DrugRepV_7814	2-(5-bromopyridin-3-yl)-1-[5-(4-chlorophenyl)furan-2-yl]-2-fluoroethanone	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	18295820
DrugRepV_7816	ML300	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	24080461
DrugRepV_7817	2-(benzotriazol-1-yl)-N-(4-phenylphenyl)-N-(thiophen-3-ylmethyl)acetamide	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	24080461
DrugRepV_7826	N-[4-[[2-(benzotriazol-1-yl)acetyl]-(thiophen-3-ylmethyl)amino]phenyl]propanamide	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	24080461
DrugRepV_7827	N-[4-[[2-(benzotriazol-1-yl)acetyl]-(thiophen-3-ylmethyl)amino]phenyl]-2-methylpropanamide	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	24080461
DrugRepV_7828	N-{4-[(1H-Benzotriazol-1-ylacetyl)(3-thienylmethyl)amino]phenyl}-2,2-dimethylpropanamide	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	24080461
DrugRepV_7829	N-[4-[[2-(benzotriazol-1-yl)acetyl]-(thiophen-3-ylmethyl)amino]phenyl]-3-methoxypropanamide	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	24080461
DrugRepV_7830	N-[4-[[2-(benzotriazol-1-yl)acetyl]-(thiophen-3-ylmethyl)amino]phenyl]cyclobutanecarboxamide	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	24080461
DrugRepV_7831	N-[4-[[2-(benzotriazol-1-yl)acetyl]-(thiophen-3-ylmethyl)amino]phenyl]cyclohexanecarboxamide	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	24080461
DrugRepV_7832	N-[4-[[2-(benzotriazol-1-yl)acetyl]-(thiophen-3-ylmethyl)amino]phenyl]benzamide	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	24080461
DrugRepV_7833	2-methylpropyl N-[4-[[2-(benzotriazol-1-yl)acetyl]-(thiophen-3-ylmethyl)amino]phenyl]carbamate	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	24080461
DrugRepV_7834	2-(benzotriazol-1-yl)-N-[4-(methylamino)phenyl]-N-(thiophen-3-ylmethyl)acetamide	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	24080461
DrugRepV_7835	2-(benzotriazol-1-yl)-N-[4-(benzylamino)phenyl]-N-(thiophen-3-ylmethyl)acetamide	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	24080461
DrugRepV_7836	2-(benzotriazol-1-yl)-N-(4-pyridin-3-ylphenyl)-N-(thiophen-3-ylmethyl)acetamide	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	24080461
DrugRepV_7837	2-(benzotriazol-1-yl)-N-[4-(2-methoxypyridin-3-yl)phenyl]-N-(thiophen-3-ylmethyl)acetamide	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	24080461
DrugRepV_7838	2-(benzotriazol-1-yl)-N-(4-pyridin-4-ylphenyl)-N-(thiophen-3-ylmethyl)acetamide	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	24080461
DrugRepV_7839	2-(benzotriazol-1-yl)-N-[4-(2-methoxypyrimidin-5-yl)phenyl]-N-(thiophen-3-ylmethyl)acetamide	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	24080461
DrugRepV_7882	5-chloropyridin-3-yl 5-(4-chlorophenyl)oxolane-2-carboxylate	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	17931870
DrugRepV_7883	5-chloropyridin-3-yl 5-(4-nitrophenyl)oxolane-2-carboxylate	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	17931870
DrugRepV_7884	5-chloropyridin-3-yl 5-(4-chloro-2-nitrophenyl)oxolane-2-carboxylate	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	17931870
DrugRepV_7885	5-chloropyridin-3-yl 5-(2-nitrophenyl)oxolane-2-carboxylate	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	17931870
DrugRepV_7886	5-chloropyridin-3-yl 5-(3-nitrophenyl)oxolane-2-carboxylate	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	17931870
DrugRepV_7887	(5-chloropyridin-3-yl) pyridine-4-carboxylate	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	17931870
DrugRepV_7888	(5-chloropyridin-3-yl) pyridine-3-carboxylate	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	17931870
DrugRepV_7889	(5-chloropyridin-3-yl) 4-chlorobenzoate	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	17931870
DrugRepV_7890	(5-chloropyridin-3-yl) 2-nitrobenzoate	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	17931870
DrugRepV_7891	(5-chloropyridin-3-yl) 3-nitrobenzoate	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	17931870
DrugRepV_7892	5-Chloro-3-pyridinyl 1-naphthoate	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	17931870
DrugRepV_7893	(5-chloropyridin-3-yl) 2-oxochromene-3-carboxylate	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	17931870
DrugRepV_7897	Ouabain	Cardiovascular agents	Atrial fibrillation and flutter | Heart failure	Japanese encephalitis virus	NA		NA	Decrease (50 %)	Approved	31871089
DrugRepV_7898	Digoxin	Cardiovascular agents	Arrhythmia	Japanese encephalitis virus	NA		NA	Decrease (50 %)	Approved	31871089
DrugRepV_7899	Lycorine	NA	NA	Japanese encephalitis virus	NA		NA	Decrease (50 %)	NA	31871089
DrugRepV_7900	Cephalotaxlen	NA	NA	Japanese encephalitis virus	NA		NA	Decrease (50 %)	NA	31871089
DrugRepV_7901	Schisandrin B	NA	NA	Japanese encephalitis virus	NA		NA	Decrease (50 %)	NA	31871089
DrugRepV_7902	Procyanidin	NA	NA	Japanese encephalitis virus	NA		NA	Decrease (50 %)	NA	31871089
DrugRepV_7903	Emodin	NA	Polycystic Kidney	Japanese encephalitis virus	NA		NA	Decrease (50 %)	Investigational	31871089
DrugRepV_7904	Schisandrin B	NA	NA	Japanese encephalitis virus	NA		NA	Decrease (50 %)	NA	31871089
DrugRepV_7942	DHBNH	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	32151066
DrugRepV_7943	3-[(E)-{[(3,4-dihydroxyphenyl)formamido]imino}methyl]-[1,1'-biphenyl]-4-carboxylic acid	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	32151066
DrugRepV_7944	(3E)-3-{2-[4-(3,4-dihydroxyphenyl)-1,3-thiazol-2-yl]hydrazin-1-ylidene}-2,3-dihydro-1H-indol-2-one	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	32151066
DrugRepV_7945	4-[2-[(2-hydroxy-1H-indol-3-yl)diazenyl]-1,3-thiazol-4-yl]benzonitrile	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	32151066
DrugRepV_7946	NSC727447	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	32151066
DrugRepV_7947	NSC732665	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	32151066
DrugRepV_7948	2-(3,4-Dihydroxyphenyl)-1,5,6,7,8,9-hexahydro-4H-cyclohepta[4,5]thieno[2,3-d]pyrimidin-4-one	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	32151066
DrugRepV_7949	2-(3,4-dihydroxybenzamido)-N-(pyridin-2-yl)-4H,5H,6H,7H,8H-cyclohepta[b]thiophene-3-carboxamide	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	32151066
DrugRepV_7950	5-(3,4-dihydroxyphenyl)-4-oxa-8-thia-6-azatricyclo[7.4.0.0²,?]trideca-1(9),2(7),5,10,12-pentaen-3-one	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	32151066
DrugRepV_7951	(E)-3-(3,4-dihydroxyphenyl)-N-[(Z)-octadec-9-enyl]prop-2-enamide	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	32151066
DrugRepV_7952	4-Butoxy-N-(5-methyl-7-phenyl-4,7-dihydro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)benzamide	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	32151066
DrugRepV_7953	4-Butyl-N-(5-methyl-7-phenyl-4,7-dihydro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)benzamide	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	32151066
DrugRepV_7954	4-butyl-N-{5-methyl-7-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}benzamide	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	32151066
DrugRepV_7955	2-fluoro-N-{5-methyl-7-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}benzamide	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	32151066
DrugRepV_7956	N-{5-methyl-7-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}-4-nitrobenzamide	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	32151066
DrugRepV_7957	4-amino-N-{5-methyl-7-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}benzamide	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	32151066
DrugRepV_7958	3,4-dimethoxy-N-{5-methyl-7-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}benzamide	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	32151066
DrugRepV_7959	3,4-dihydroxy-N-{5-methyl-7-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}benzamide	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	32151066
DrugRepV_7960	2-fluoro-N-{7-methyl-5-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}benzamide	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	32151066
DrugRepV_7961	N-{7-methyl-5-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}-4-nitrobenzamide	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	32151066
DrugRepV_7962	4-amino-N-{7-methyl-5-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}benzamide	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	32151066
DrugRepV_7963	3,4-dimethoxy-N-{7-methyl-5-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}benzamide	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	32151066
DrugRepV_7964	3,4-dihydroxy-N-{7-methyl-5-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}benzamide	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	32151066
DrugRepV_7965	4-butyl-N-{5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}benzamide	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	32151066
DrugRepV_7966	N-{5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}-2-fluorobenzamide	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	32151066
DrugRepV_7967	N-{5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}-4-nitrobenzamide	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	32151066
DrugRepV_7968	4-amino-N-{5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}benzamide	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	32151066
DrugRepV_7969	N-{5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}-3,4-dimethoxybenzamide	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	32151066
DrugRepV_7970	N-{5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}-3,4-dihydroxybenzamide	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	32151066
DrugRepV_7971	N-{5,7-diphenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}-3,4-dihydroxybenzamide	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	32151066
DrugRepV_7972	N-[7-(3,4-dihydroxyphenyl)-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl]benzamide	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	32151066
DrugRepV_7973	N-benzoyl-N-[7-(3,4-dimethoxyphenyl)-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl]benzamide	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	32151066
DrugRepV_7974	N-(3,4-dihydroxyphenyl)-5-methyl-7-phenyl-[1,2,4]triazolo[1,5-a]pyrimidine-2-carboxamide	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	32151066
DrugRepV_7975	N-(3,4-dihydroxyphenyl)-7-methyl-5-phenyl-[1,2,4]triazolo[1,5-a]pyrimidine-2-carboxamide	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	32151066
DrugRepV_7988	2-(6-{[1-carboxy-2-(2-phenyl-1H-indol-3-yl)ethyl]carbamoyl}-4-(2-{[1-carboxy-2-(2-phenyl-1H-indol-3-yl)ethyl]carbamoyl}ethyl)-4-nitrohexanamido)-3-(2-phenyl-1H-indol-3-yl)propanoic acid	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31809045
DrugRepV_7989	2-[6-({1-carboxy-2-[2-(2-fluorophenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(2-fluorophenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]-3-[2-(2-fluorophenyl)-1H-indol-3-yl]propanoic acid	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31809045
DrugRepV_7990	2-[6-({1-carboxy-2-[2-(4-nitrophenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(4-nitrophenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]-3-[2-(4-nitrophenyl)-1H-indol-3-yl]propanoic acid	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31809045
DrugRepV_7991	3-[2-(4-bromophenyl)-1H-indol-3-yl]-2-[6-({2-[2-(4-bromophenyl)-1H-indol-3-yl]-1-carboxyethyl}carbamoyl)-4-[2-({2-[2-(4-bromophenyl)-1H-indol-3-yl]-1-carboxyethyl}carbamoyl)ethyl]-4-nitrohexanamido]propanoic acid	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31809045
DrugRepV_7992	2-{6-[(1-carboxy-2-{2-[4-(trifluoromethyl)phenyl]-1H-indol-3-yl}ethyl)carbamoyl]-4-{2-[(1-carboxy-2-{2-[4-(trifluoromethyl)phenyl]-1H-indol-3-yl}ethyl)carbamoyl]ethyl}-4-nitrohexanamido}-3-{2-[4-(trifluoromethyl)phenyl]-1H-indol-3-yl}propanoic acid	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31809045
DrugRepV_7993	2-[6-({1-carboxy-2-[2-(4-methoxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(4-methoxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]-3-[2-(4-methoxyphenyl)-1H-indol-3-yl]propanoic acid	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31809045
DrugRepV_7994	3-(3-{2-carboxy-2-[6-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]ethyl}-1H-indol-2-yl)benzoic acid	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31809045
DrugRepV_7995	4-(3-{2-carboxy-2-[6-({1-carboxy-2-[2-(4-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(4-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]ethyl}-1H-indol-2-yl)benzoic acid	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31809045
DrugRepV_7996	5-(3-{2-carboxy-2-[6-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]ethyl}-1H-indol-2-yl)benzene-1,3-dicarboxylic acid	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31809045
DrugRepV_7997	3-{3-[2-carboxy-2-(3-{3-[2-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]-2,2-bis({[2-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]methyl})propoxy}propanamido)ethyl]-1H-indol-2-yl}benzoic acid	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31809045
DrugRepV_7998	4-{3-[2-carboxy-2-(3-{3-[2-({1-carboxy-2-[2-(4-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]-2,2-bis({[2-({1-carboxy-2-[2-(4-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]methyl})propoxy}propanamido)ethyl]-1H-indol-2-yl}benzoic acid	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31809045
DrugRepV_7999	5-{3-[2-carboxy-2-(3-{3-[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]-2,2-bis({[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]methyl})propoxy}propanamido)ethyl]-1H-indol-2-yl}benzene-1	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31809045
DrugRepV_8000	3-(1-benzyl-1H-indol-3-yl)-2-(6-{[2-(1-benzyl-1H-indol-3-yl)-1-carboxyethyl]carbamoyl}-4-(2-{[2-(1-benzyl-1H-indol-3-yl)-1-carboxyethyl]carbamoyl}ethyl)-4-nitrohexanamido)propanoic acid	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31809045
DrugRepV_8001	2-{6-[(1-carboxy-2-{1-[(4-fluorophenyl)methyl]-1H-indol-3-yl}ethyl)carbamoyl]-4-{2-[(1-carboxy-2-{1-[(4-fluorophenyl)methyl]-1H-indol-3-yl}ethyl)carbamoyl]ethyl}-4-nitrohexanamido}-3-{1-[(4-fluorophenyl)methyl]-1H-indol-3-yl}propanoic acid	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31809045
DrugRepV_8002	4-{[3-(2-carboxy-2-{6-[(1-carboxy-2-{1-[(4-carboxyphenyl)methyl]-1H-indol-3-yl}ethyl)carbamoyl]-4-{2-[(1-carboxy-2-{1-[(4-carboxyphenyl)methyl]-1H-indol-3-yl}ethyl)carbamoyl]ethyl}-4-nitrohexanamido}ethyl)-1H-indol-1-yl]methyl}benzoic acid	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31809045
DrugRepV_8003	4-[(3-{2-carboxy-2-[3-(3-{2-[(1-carboxy-2-{1-[(4-carboxyphenyl)methyl]-1H-indol-3-yl}ethyl)carbamoyl]ethoxy}-2,2-bis({2-[(1-carboxy-2-{1-[(4-carboxyphenyl)methyl]-1H-indol-3-yl}ethyl)carbamoyl]ethoxy}methyl)propoxy)propanamido]ethyl}-1H-indol-1-yl)me	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31809045
DrugRepV_8004	2-(6-{[1-carboxy-2-(2-phenyl-1H-indol-3-yl)ethyl]carbamoyl}-4-(2-{[1-carboxy-2-(2-phenyl-1H-indol-3-yl)ethyl]carbamoyl}ethyl)-4-nitrohexanamido)-3-(2-phenyl-1H-indol-3-yl)propanoic acid	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31809045
DrugRepV_8005	2-[6-({1-carboxy-2-[2-(2-fluorophenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(2-fluorophenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]-3-[2-(2-fluorophenyl)-1H-indol-3-yl]propanoic acid	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31809045
DrugRepV_8006	2-[6-({1-carboxy-2-[2-(4-nitrophenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(4-nitrophenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]-3-[2-(4-nitrophenyl)-1H-indol-3-yl]propanoic acid	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31809045
DrugRepV_8007	3-[2-(4-bromophenyl)-1H-indol-3-yl]-2-[6-({2-[2-(4-bromophenyl)-1H-indol-3-yl]-1-carboxyethyl}carbamoyl)-4-[2-({2-[2-(4-bromophenyl)-1H-indol-3-yl]-1-carboxyethyl}carbamoyl)ethyl]-4-nitrohexanamido]propanoic acid	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31809045
DrugRepV_8008	2-{6-[(1-carboxy-2-{2-[4-(trifluoromethyl)phenyl]-1H-indol-3-yl}ethyl)carbamoyl]-4-{2-[(1-carboxy-2-{2-[4-(trifluoromethyl)phenyl]-1H-indol-3-yl}ethyl)carbamoyl]ethyl}-4-nitrohexanamido}-3-{2-[4-(trifluoromethyl)phenyl]-1H-indol-3-yl}propanoic acid	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31809045
DrugRepV_8009	2-[6-({1-carboxy-2-[2-(4-methoxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(4-methoxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]-3-[2-(4-methoxyphenyl)-1H-indol-3-yl]propanoic acid	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31809045
DrugRepV_8010	3-(3-{2-carboxy-2-[6-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]ethyl}-1H-indol-2-yl)benzoic acid	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31809045
DrugRepV_8011	4-(3-{2-carboxy-2-[6-({1-carboxy-2-[2-(4-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(4-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]ethyl}-1H-indol-2-yl)benzoic acid	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31809045
DrugRepV_8012	5-(3-{2-carboxy-2-[6-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]ethyl}-1H-indol-2-yl)benzene-1,3-dicarboxylic acid	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31809045
DrugRepV_8013	3-{3-[2-carboxy-2-(3-{3-[2-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]-2,2-bis({[2-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]methyl})propoxy}propanamido)ethyl]-1H-indol-2-yl}benzoic acid	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31809045
DrugRepV_8014	4-{3-[2-carboxy-2-(3-{3-[2-({1-carboxy-2-[2-(4-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]-2,2-bis({[2-({1-carboxy-2-[2-(4-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]methyl})propoxy}propanamido)ethyl]-1H-indol-2-yl}benzoic acid	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31809045
DrugRepV_8015	5-{3-[2-carboxy-2-(3-{3-[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]-2,2-bis({[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]methyl})propoxy}propanamido)ethyl]-1H-indol-2-yl}benzene-1	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31809045
DrugRepV_8016	3-(1-benzyl-1H-indol-3-yl)-2-(6-{[2-(1-benzyl-1H-indol-3-yl)-1-carboxyethyl]carbamoyl}-4-(2-{[2-(1-benzyl-1H-indol-3-yl)-1-carboxyethyl]carbamoyl}ethyl)-4-nitrohexanamido)propanoic acid	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31809045
DrugRepV_8017	2-{6-[(1-carboxy-2-{1-[(4-fluorophenyl)methyl]-1H-indol-3-yl}ethyl)carbamoyl]-4-{2-[(1-carboxy-2-{1-[(4-fluorophenyl)methyl]-1H-indol-3-yl}ethyl)carbamoyl]ethyl}-4-nitrohexanamido}-3-{1-[(4-fluorophenyl)methyl]-1H-indol-3-yl}propanoic acid	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31809045
DrugRepV_8018	4-{[3-(2-carboxy-2-{6-[(1-carboxy-2-{1-[(4-carboxyphenyl)methyl]-1H-indol-3-yl}ethyl)carbamoyl]-4-{2-[(1-carboxy-2-{1-[(4-carboxyphenyl)methyl]-1H-indol-3-yl}ethyl)carbamoyl]ethyl}-4-nitrohexanamido}ethyl)-1H-indol-1-yl]methyl}benzoic acid	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31809045
DrugRepV_8019	4-[(3-{2-carboxy-2-[3-(3-{2-[(1-carboxy-2-{1-[(4-carboxyphenyl)methyl]-1H-indol-3-yl}ethyl)carbamoyl]ethoxy}-2,2-bis({2-[(1-carboxy-2-{1-[(4-carboxyphenyl)methyl]-1H-indol-3-yl}ethyl)carbamoyl]ethoxy}methyl)propoxy)propanamido]ethyl}-1H-indol-1-yl)me	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31809045
DrugRepV_8020	2-(6-{[1-carboxy-2-(2-phenyl-1H-indol-3-yl)ethyl]carbamoyl}-4-(2-{[1-carboxy-2-(2-phenyl-1H-indol-3-yl)ethyl]carbamoyl}ethyl)-4-nitrohexanamido)-3-(2-phenyl-1H-indol-3-yl)propanoic acid	NA	NA	Enterovirus	BrCr		NA	Decrease (50 %)	NA	31809045
DrugRepV_8021	2-[6-({1-carboxy-2-[2-(2-fluorophenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(2-fluorophenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]-3-[2-(2-fluorophenyl)-1H-indol-3-yl]propanoic acid	NA	NA	Enterovirus	BrCr		NA	Decrease (50 %)	NA	31809045
DrugRepV_8022	2-[6-({1-carboxy-2-[2-(4-nitrophenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(4-nitrophenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]-3-[2-(4-nitrophenyl)-1H-indol-3-yl]propanoic acid	NA	NA	Enterovirus	BrCr		NA	Decrease (50 %)	NA	31809045
DrugRepV_8023	3-[2-(4-bromophenyl)-1H-indol-3-yl]-2-[6-({2-[2-(4-bromophenyl)-1H-indol-3-yl]-1-carboxyethyl}carbamoyl)-4-[2-({2-[2-(4-bromophenyl)-1H-indol-3-yl]-1-carboxyethyl}carbamoyl)ethyl]-4-nitrohexanamido]propanoic acid	NA	NA	Enterovirus	BrCr		NA	Decrease (50 %)	NA	31809045
DrugRepV_8024	2-{6-[(1-carboxy-2-{2-[4-(trifluoromethyl)phenyl]-1H-indol-3-yl}ethyl)carbamoyl]-4-{2-[(1-carboxy-2-{2-[4-(trifluoromethyl)phenyl]-1H-indol-3-yl}ethyl)carbamoyl]ethyl}-4-nitrohexanamido}-3-{2-[4-(trifluoromethyl)phenyl]-1H-indol-3-yl}propanoic acid	NA	NA	Enterovirus	BrCr		NA	Decrease (50 %)	NA	31809045
DrugRepV_8025	2-[6-({1-carboxy-2-[2-(4-methoxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(4-methoxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]-3-[2-(4-methoxyphenyl)-1H-indol-3-yl]propanoic acid	NA	NA	Enterovirus	BrCr		NA	Decrease (50 %)	NA	31809045
DrugRepV_8026	3-(3-{2-carboxy-2-[6-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]ethyl}-1H-indol-2-yl)benzoic acid	NA	NA	Enterovirus	BrCr		NA	Decrease (50 %)	NA	31809045
DrugRepV_8027	4-(3-{2-carboxy-2-[6-({1-carboxy-2-[2-(4-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(4-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]ethyl}-1H-indol-2-yl)benzoic acid	NA	NA	Enterovirus	BrCr		NA	Decrease (50 %)	NA	31809045
DrugRepV_8028	5-(3-{2-carboxy-2-[6-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]ethyl}-1H-indol-2-yl)benzene-1,3-dicarboxylic acid	NA	NA	Enterovirus	BrCr		NA	Decrease (50 %)	NA	31809045
DrugRepV_8029	3-{3-[2-carboxy-2-(3-{3-[2-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]-2,2-bis({[2-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]methyl})propoxy}propanamido)ethyl]-1H-indol-2-yl}benzoic acid	NA	NA	Enterovirus	BrCr		NA	Decrease (50 %)	NA	31809045
DrugRepV_8030	4-{3-[2-carboxy-2-(3-{3-[2-({1-carboxy-2-[2-(4-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]-2,2-bis({[2-({1-carboxy-2-[2-(4-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]methyl})propoxy}propanamido)ethyl]-1H-indol-2-yl}benzoic acid	NA	NA	Enterovirus	BrCr		NA	Decrease (50 %)	NA	31809045
DrugRepV_8031	5-{3-[2-carboxy-2-(3-{3-[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]-2,2-bis({[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]methyl})propoxy}propanamido)ethyl]-1H-indol-2-yl}benzene-1	NA	NA	Enterovirus	BrCr		NA	Decrease (50 %)	NA	31809045
DrugRepV_8032	4-[(3-{2-carboxy-2-[3-(3-{2-[(1-carboxy-2-{1-[(4-carboxyphenyl)methyl]-1H-indol-3-yl}ethyl)carbamoyl]ethoxy}-2,2-bis({2-[(1-carboxy-2-{1-[(4-carboxyphenyl)methyl]-1H-indol-3-yl}ethyl)carbamoyl]ethoxy}methyl)propoxy)propanamido]ethyl}-1H-indol-1-yl)me	NA	NA	Enterovirus	BrCr		NA	Decrease (50 %)	NA	31809045
DrugRepV_8033	2-[6-({1-carboxy-2-[2-(4-nitrophenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(4-nitrophenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]-3-[2-(4-nitrophenyl)-1H-indol-3-yl]propanoic acid	NA	NA	Enterovirus	BrCr		NA	Decrease (90 %)	NA	31809045
DrugRepV_8034	3-(3-{2-carboxy-2-[6-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]ethyl}-1H-indol-2-yl)benzoic acid	NA	NA	Enterovirus	BrCr		NA	Decrease (90 %)	NA	31809045
DrugRepV_8035	5-(3-{2-carboxy-2-[6-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]ethyl}-1H-indol-2-yl)benzene-1,3-dicarboxylic acid	NA	NA	Enterovirus	BrCr		NA	Decrease (90 %)	NA	31809045
DrugRepV_8036	3-{3-[2-carboxy-2-(3-{3-[2-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]-2,2-bis({[2-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]methyl})propoxy}propanamido)ethyl]-1H-indol-2-yl}benzoic acid	NA	NA	Enterovirus	BrCr		NA	Decrease (90 %)	NA	31809045
DrugRepV_8037	4-{3-[2-carboxy-2-(3-{3-[2-({1-carboxy-2-[2-(4-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]-2,2-bis({[2-({1-carboxy-2-[2-(4-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]methyl})propoxy}propanamido)ethyl]-1H-indol-2-yl}benzoic acid	NA	NA	Enterovirus	BrCr		NA	Decrease (90 %)	NA	31809045
DrugRepV_8038	5-{3-[2-carboxy-2-(3-{3-[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]-2,2-bis({[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]methyl})propoxy}propanamido)ethyl]-1H-indol-2-yl}benzene-1	NA	NA	Enterovirus	BrCr		NA	Decrease (90 %)	NA	31809045
DrugRepV_8039	MADAL-385	NA	NA	Enterovirus	11316		NA	Decrease (50 %)	NA	31809045
DrugRepV_8040	5-(3-{2-carboxy-2-[6-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]ethyl}-1H-indol-2-yl)benzene-1,3-dicarboxylic acid	NA	NA	Enterovirus	11316		NA	Decrease (50 %)	NA	31809045
DrugRepV_8041	3-{3-[2-carboxy-2-(3-{3-[2-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]-2,2-bis({[2-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]methyl})propoxy}propanamido)ethyl]-1H-indol-2-yl}benzoic acid	NA	NA	Enterovirus	11316		NA	Decrease (50 %)	NA	31809045
DrugRepV_8042	5-{3-[2-carboxy-2-(3-{3-[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]-2,2-bis({[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]methyl})propoxy}propanamido)ethyl]-1H-indol-2-yl}benzene-1	NA	NA	Enterovirus	11316		NA	Decrease (50 %)	NA	31809045
DrugRepV_8043	MADAL-385	NA	NA	Enterovirus	TW/70902/08		NA	Decrease (50 %)	NA	31809045
DrugRepV_8044	5-(3-{2-carboxy-2-[6-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]ethyl}-1H-indol-2-yl)benzene-1,3-dicarboxylic acid	NA	NA	Enterovirus	TW/70902/08		NA	Decrease (50 %)	NA	31809045
DrugRepV_8045	3-{3-[2-carboxy-2-(3-{3-[2-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]-2,2-bis({[2-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]methyl})propoxy}propanamido)ethyl]-1H-indol-2-yl}benzoic acid	NA	NA	Enterovirus	TW/70902/08		NA	Decrease (50 %)	NA	31809045
DrugRepV_8046	5-{3-[2-carboxy-2-(3-{3-[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]-2,2-bis({[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]methyl})propoxy}propanamido)ethyl]-1H-indol-2-yl}benzene-1	NA	NA	Enterovirus	TW/70902/08		NA	Decrease (50 %)	NA	31809045
DrugRepV_8047	MADAL-385	NA	NA	Enterovirus	H08300 461; 812		NA	Decrease (50 %)	NA	31809045
DrugRepV_8048	5-(3-{2-carboxy-2-[6-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]ethyl}-1H-indol-2-yl)benzene-1,3-dicarboxylic acid	NA	NA	Enterovirus	H08300 461; 812		NA	Decrease (50 %)	NA	31809045
DrugRepV_8049	3-{3-[2-carboxy-2-(3-{3-[2-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]-2,2-bis({[2-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]methyl})propoxy}propanamido)ethyl]-1H-indol-2-yl}benzoic acid	NA	NA	Enterovirus	H08300 461; 812		NA	Decrease (50 %)	NA	31809045
DrugRepV_8050	5-{3-[2-carboxy-2-(3-{3-[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]-2,2-bis({[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]methyl})propoxy}propanamido)ethyl]-1H-indol-2-yl}benzene-1	NA	NA	Enterovirus	H08300 461; 812		NA	Decrease (50 %)	NA	31809045
DrugRepV_8051	MADAL-385	NA	NA	Enterovirus	TW/1956/05		NA	Decrease (50 %)	NA	31809045
DrugRepV_8052	5-(3-{2-carboxy-2-[6-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]ethyl}-1H-indol-2-yl)benzene-1,3-dicarboxylic acid	NA	NA	Enterovirus	TW/1956/05		NA	Decrease (50 %)	NA	31809045
DrugRepV_8053	3-{3-[2-carboxy-2-(3-{3-[2-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]-2,2-bis({[2-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]methyl})propoxy}propanamido)ethyl]-1H-indol-2-yl}benzoic acid	NA	NA	Enterovirus	TW/1956/05		NA	Decrease (50 %)	NA	31809045
DrugRepV_8054	5-{3-[2-carboxy-2-(3-{3-[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]-2,2-bis({[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]methyl})propoxy}propanamido)ethyl]-1H-indol-2-yl}benzene-1	NA	NA	Enterovirus	TW/1956/05		NA	Decrease (50 %)	NA	31809045
DrugRepV_8055	4-{[6-chloro-4-({2,6-dichloro-4-[(1E)-2-cyanoeth-1-en-1-yl]phenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		NA	Decrease (50 %)	NA	31599568
DrugRepV_8056	4-{[6-chloro-4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-difluorophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		NA	Decrease (50 %)	NA	31599568
DrugRepV_8057	4-{[6-chloro-4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-fluoro-6-methylphenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		NA	Decrease (50 %)	NA	31599568
DrugRepV_8058	4-{[6-chloro-4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-methyl-6-nitrophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		NA	Decrease (50 %)	NA	31599568
DrugRepV_8059	4-{[6-chloro-4-({2,6-dichloro-4-[(1E)-2-cyanoeth-1-en-1-yl]phenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K		NA	Decrease (50 %)	NA	31599568
DrugRepV_8060	4-{[6-chloro-4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-difluorophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K		NA	Decrease (50 %)	NA	31599568
DrugRepV_8061	4-{[6-chloro-4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-fluoro-6-methylphenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K		NA	Decrease (50 %)	NA	31599568
DrugRepV_8062	4-{[6-chloro-4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-methyl-6-nitrophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K		NA	Decrease (50 %)	NA	31599568
DrugRepV_8063	4-{[6-chloro-4-({2,6-dichloro-4-[(1E)-2-cyanoeth-1-en-1-yl]phenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N		NA	Decrease (50 %)	NA	31599568
DrugRepV_8064	4-{[6-chloro-4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-difluorophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N		NA	Decrease (50 %)	NA	31599568
DrugRepV_8065	4-{[6-chloro-4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-fluoro-6-methylphenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N		NA	Decrease (50 %)	NA	31599568
DrugRepV_8066	4-{[6-chloro-4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-methyl-6-nitrophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N		NA	Decrease (50 %)	NA	31599568
DrugRepV_8067	4-{[6-chloro-4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-methyl-6-nitrophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		NA	Decrease (50 %)	NA	31599568
DrugRepV_8068	4-{[4-({2-chloro-4-[(1E)-2-cyanoeth-1-en-1-yl]-6-fluorophenyl}amino)-6-fluoroquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		NA	Decrease (50 %)	NA	31599568
DrugRepV_8069	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-difluorophenyl}amino)-6-fluoroquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		NA	Decrease (50 %)	NA	31599568
DrugRepV_8070	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-fluoro-6-methylphenyl}amino)-6-fluoroquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		NA	Decrease (50 %)	NA	31599568
DrugRepV_8071	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-methyl-6-nitrophenyl}amino)-6-fluoroquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		NA	Decrease (50 %)	NA	31599568
DrugRepV_8072	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-dimethylphenyl}amino)-6-methoxyquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		NA	Decrease (50 %)	NA	31599568
DrugRepV_8073	4-{[4-({2,6-dichloro-4-[(1E)-2-cyanoeth-1-en-1-yl]phenyl}amino)-6-methoxyquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		NA	Decrease (50 %)	NA	31599568
DrugRepV_8074	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-difluorophenyl}amino)-6-methoxyquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		NA	Decrease (50 %)	NA	31599568
DrugRepV_8075	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-difluorophenyl}amino)-6-hydroxyquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		NA	Decrease (50 %)	NA	31599568
DrugRepV_8076	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-difluorophenyl}amino)-6-nitroquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		NA	Decrease (50 %)	NA	31599568
DrugRepV_8077	4-{[7-chloro-4-({2,6-dichloro-4-[(1E)-2-cyanoeth-1-en-1-yl]phenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		NA	Decrease (50 %)	NA	31599568
DrugRepV_8078	4-{[7-chloro-4-({2-chloro-4-[(1E)-2-cyanoeth-1-en-1-yl]-6-fluorophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		NA	Decrease (50 %)	NA	31599568
DrugRepV_8079	4-{[7-chloro-4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-difluorophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		NA	Decrease (50 %)	NA	31599568
DrugRepV_8080	4-{[7-chloro-4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-fluoro-6-methylphenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		NA	Decrease (50 %)	NA	31599568
DrugRepV_8081	4-{[7-chloro-4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-methyl-6-nitrophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		NA	Decrease (50 %)	NA	31599568
DrugRepV_8082	4-{[4-({2-amino-4-[(1E)-2-cyanoeth-1-en-1-yl]-6-methylphenyl}amino)-7-chloroquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		NA	Decrease (50 %)	NA	31599568
DrugRepV_8083	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-dimethylphenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		NA	Decrease (50 %)	NA	31599568
DrugRepV_8084	4-{[4-({2,6-dichloro-4-[(1E)-2-cyanoeth-1-en-1-yl]phenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		NA	Decrease (50 %)	NA	31599568
DrugRepV_8085	4-{[4-({2-chloro-4-[(1E)-2-cyanoeth-1-en-1-yl]-6-fluorophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		NA	Decrease (50 %)	NA	31599568
DrugRepV_8086	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-difluorophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		NA	Decrease (50 %)	NA	31599568
DrugRepV_8087	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-fluoro-6-methylphenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		NA	Decrease (50 %)	NA	31599568
DrugRepV_8088	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-methyl-6-nitrophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		NA	Decrease (50 %)	NA	31599568
DrugRepV_8089	4-{[6-chloro-4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-methyl-6-nitrophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K		NA	Decrease (50 %)	NA	31599568
DrugRepV_8090	4-{[4-({2-chloro-4-[(1E)-2-cyanoeth-1-en-1-yl]-6-fluorophenyl}amino)-6-fluoroquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K		NA	Decrease (50 %)	NA	31599568
DrugRepV_8091	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-difluorophenyl}amino)-6-fluoroquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K		NA	Decrease (50 %)	NA	31599568
DrugRepV_8092	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-fluoro-6-methylphenyl}amino)-6-fluoroquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K		NA	Decrease (50 %)	NA	31599568
DrugRepV_8093	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-methyl-6-nitrophenyl}amino)-6-fluoroquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K		NA	Decrease (50 %)	NA	31599568
DrugRepV_8094	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-dimethylphenyl}amino)-6-methoxyquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K		NA	Decrease (50 %)	NA	31599568
DrugRepV_8095	4-{[4-({2,6-dichloro-4-[(1E)-2-cyanoeth-1-en-1-yl]phenyl}amino)-6-methoxyquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K		NA	Decrease (50 %)	NA	31599568
DrugRepV_8096	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-difluorophenyl}amino)-6-methoxyquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K		NA	Decrease (50 %)	NA	31599568
DrugRepV_8097	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-difluorophenyl}amino)-6-hydroxyquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K		NA	Decrease (50 %)	NA	31599568
DrugRepV_8098	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-difluorophenyl}amino)-6-nitroquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K		NA	Decrease (50 %)	NA	31599568
DrugRepV_8099	4-{[7-chloro-4-({2,6-dichloro-4-[(1E)-2-cyanoeth-1-en-1-yl]phenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K		NA	Decrease (50 %)	NA	31599568
DrugRepV_8100	4-{[7-chloro-4-({2-chloro-4-[(1E)-2-cyanoeth-1-en-1-yl]-6-fluorophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K		NA	Decrease (50 %)	NA	31599568
DrugRepV_8101	4-{[7-chloro-4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-difluorophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K		NA	Decrease (50 %)	NA	31599568
DrugRepV_8102	4-{[7-chloro-4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-fluoro-6-methylphenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K		NA	Decrease (50 %)	NA	31599568
DrugRepV_8103	4-{[7-chloro-4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-methyl-6-nitrophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K		NA	Decrease (50 %)	NA	31599568
DrugRepV_8104	4-{[4-({2-amino-4-[(1E)-2-cyanoeth-1-en-1-yl]-6-methylphenyl}amino)-7-chloroquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K		NA	Decrease (50 %)	NA	31599568
DrugRepV_8105	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-dimethylphenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K		NA	Decrease (50 %)	NA	31599568
DrugRepV_8106	4-{[4-({2,6-dichloro-4-[(1E)-2-cyanoeth-1-en-1-yl]phenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K		NA	Decrease (50 %)	NA	31599568
DrugRepV_8107	4-{[4-({2-chloro-4-[(1E)-2-cyanoeth-1-en-1-yl]-6-fluorophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K		NA	Decrease (50 %)	NA	31599568
DrugRepV_8108	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-difluorophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K		NA	Decrease (50 %)	NA	31599568
DrugRepV_8109	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-fluoro-6-methylphenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K		NA	Decrease (50 %)	NA	31599568
DrugRepV_8110	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-methyl-6-nitrophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K		NA	Decrease (50 %)	NA	31599568
DrugRepV_8111	4-{[6-chloro-4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-methyl-6-nitrophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N		NA	Decrease (50 %)	NA	31599568
DrugRepV_8112	4-{[4-({2-chloro-4-[(1E)-2-cyanoeth-1-en-1-yl]-6-fluorophenyl}amino)-6-fluoroquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N		NA	Decrease (50 %)	NA	31599568
DrugRepV_8113	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-difluorophenyl}amino)-6-fluoroquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N		NA	Decrease (50 %)	NA	31599568
DrugRepV_8114	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-fluoro-6-methylphenyl}amino)-6-fluoroquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N		NA	Decrease (50 %)	NA	31599568
DrugRepV_8115	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-methyl-6-nitrophenyl}amino)-6-fluoroquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N		NA	Decrease (50 %)	NA	31599568
DrugRepV_8116	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-dimethylphenyl}amino)-6-methoxyquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N		NA	Decrease (50 %)	NA	31599568
DrugRepV_8117	4-{[4-({2,6-dichloro-4-[(1E)-2-cyanoeth-1-en-1-yl]phenyl}amino)-6-methoxyquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N		NA	Decrease (50 %)	NA	31599568
DrugRepV_8118	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-difluorophenyl}amino)-6-methoxyquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N		NA	Decrease (50 %)	NA	31599568
DrugRepV_8119	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-difluorophenyl}amino)-6-hydroxyquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N		NA	Decrease (50 %)	NA	31599568
DrugRepV_8120	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-difluorophenyl}amino)-6-nitroquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N		NA	Decrease (50 %)	NA	31599568
DrugRepV_8121	4-{[7-chloro-4-({2,6-dichloro-4-[(1E)-2-cyanoeth-1-en-1-yl]phenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N		NA	Decrease (50 %)	NA	31599568
DrugRepV_8122	4-{[7-chloro-4-({2-chloro-4-[(1E)-2-cyanoeth-1-en-1-yl]-6-fluorophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N		NA	Decrease (50 %)	NA	31599568
DrugRepV_8123	4-{[7-chloro-4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-difluorophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N		NA	Decrease (50 %)	NA	31599568
DrugRepV_8124	4-{[7-chloro-4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-fluoro-6-methylphenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N		NA	Decrease (50 %)	NA	31599568
DrugRepV_8125	4-{[7-chloro-4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-methyl-6-nitrophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N		NA	Decrease (50 %)	NA	31599568
DrugRepV_8126	4-{[4-({2-amino-4-[(1E)-2-cyanoeth-1-en-1-yl]-6-methylphenyl}amino)-7-chloroquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N		NA	Decrease (50 %)	NA	31599568
DrugRepV_8127	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-dimethylphenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N		NA	Decrease (50 %)	NA	31599568
DrugRepV_8128	4-{[4-({2,6-dichloro-4-[(1E)-2-cyanoeth-1-en-1-yl]phenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N		NA	Decrease (50 %)	NA	31599568
DrugRepV_8129	4-{[4-({2-chloro-4-[(1E)-2-cyanoeth-1-en-1-yl]-6-fluorophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N		NA	Decrease (50 %)	NA	31599568
DrugRepV_8130	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-difluorophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N		NA	Decrease (50 %)	NA	31599568
DrugRepV_8131	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-fluoro-6-methylphenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N		NA	Decrease (50 %)	NA	31599568
DrugRepV_8132	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-methyl-6-nitrophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N		NA	Decrease (50 %)	NA	31599568
DrugRepV_8133	StemRegenin 1	NA	NA	Vaccinia virus	NA		NA	Decrease (68.1 %)	NA	32708182
DrugRepV_8134	Niclosamide	Antiparasitic products, Insectisides and Repellents	Tapeworm and intestinal fluke infections | Helminthiasis	Vaccinia virus	NA		NA	Decrease (43.7 %)	Approved	32708182
DrugRepV_8135	ICG-001	NA	NA	Vaccinia virus	NA		NA	Decrease (80.9 %)	NA	32708182
DrugRepV_8136	Nifuroxazide	Alimentary Tract And Metabolism	NA	Vaccinia virus	NA		NA	Decrease (48.8 %)	Experimental	32708182
DrugRepV_8137	NSC 319726	NA	NA	Vaccinia virus	NA		NA	Decrease (99.8 %)	NA	32708182
DrugRepV_8138	Tenovin-1	Anticancer	Cancer	Vaccinia virus	NA		NA	Decrease (32 %)	NA	32708182
DrugRepV_8139	RITA	NA	Cancer	Vaccinia virus	NA		NA	Decrease (50.2 %)	NA	32708182
DrugRepV_8140	Ciclopirox ethanolamine	Dermatologicals	Fungal infections	Vaccinia virus	NA		NA	Decrease (99.8 %)	Approved	32708182
DrugRepV_8141	Econazole Nitrate	Dermatologicals	Fungal infections	Vaccinia virus	NA		NA	Decrease (55.1 %)	Approved	32708182
DrugRepV_8142	Miconazole Nitrate	Alimentary Tract And Metabolism; Dermatologicals; Genito Urinary System and Sex Hormones; Antiinfect	Fungal infections (Tinea pedis (athlete’s foot), tinea cruris, and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum, in the treatment of cutaneous candidiasis (moniliasis), and in the treatment o	Vaccinia virus	NA		NA	Decrease (58.3 %)	Approved, Investigational, Vet approved	32708182
DrugRepV_8143	Monensin sodium salt	NA	NA	Vaccinia virus	NA		NA	Decrease (96.7 %)	Experimental, Vet approved	32708182
DrugRepV_8144	Idoxuridine	Antiinfectives For Systemic Use	Keratoconjunctivitis and Keratitis caused by herpes simplex virus	Vaccinia virus	NA		NA	Decrease (85.8 %)	Approved, Investigational	32708182
DrugRepV_8145	3-Deazaneplanocin A	NA	NA	Vaccinia virus	NA		NA	Decrease (76.8 %)	NA	32708182
DrugRepV_8146	Fludarabine	Antineoplastic and Immunomodulating Agents	Hematological malignancies	Vaccinia virus	NA		NA	Decrease (99.1 %)	Approved	32708182
DrugRepV_8147	Clofarabine	Antineoplastic and Immunomodulating Agents	Cancer	Vaccinia virus	NA		NA	Decrease (99.8 %)	Approved	32708182
DrugRepV_8148	Azaguanine-8	NA	NA	Vaccinia virus	NA		NA	Decrease (12.7 %)	Experimental	32708182
DrugRepV_8149	Cytarabine	NA	Leukemia	Vaccinia virus	NA		NA	Decrease (99.8 %)	Approved	32708182
DrugRepV_8150	Gemcitabine	Antineoplastic and Immunomodulating Agents	Ovarian cancer | Non-small cell lung cance | Adenocarcinoma of the pancreas	Vaccinia virus	NA		NA	Decrease (99.9 %)	Approved	32708182
DrugRepV_8151	Cyclocytidine Hydrochloride	NA	NA	Vaccinia virus	NA		NA	Decrease (99.8 %)	NA	32708182
DrugRepV_8152	Trifluridine	Sensory Organ	Primary keratoconjunctivitis and Herpes simplex keratitis	Vaccinia virus	NA		NA	Decrease (99.9 %)	Approved	32708182
DrugRepV_8153	Azacitidine	Antineoplastic and Immunomodulating Agents	French-American-British myelodysplastic syndrome	Vaccinia virus	NA		NA	Decrease (99.9 %)	Approved	32708182
DrugRepV_8154	Floxuridine	Anticancer	Gastrointestinal adenocarcinomas	Vaccinia virus	NA		NA	Decrease (62.6 %)	Approved	32708182
DrugRepV_8155	Abitrexate	Antineoplastic and Immunomodulating Agents	Gestational choriocarcinoma, chorioadenoma destruens, hydatidiform mole and acute lymphocytic leukemia	Vaccinia virus	NA		NA	Decrease (62.2 %)	Approved	32708182
DrugRepV_8156	Triapine	NA	Leukemia, Lung Cancer, Kidney Cancer, Prostate Cancer, and Pancreatic Cancer	Vaccinia virus	NA		NA	Decrease (99.9 %)	Investigational	32708182
DrugRepV_8157	Vidarabine	Antiinfectives For Systemic Use; Sensory Organ	Viral infections (Chickenpox, Herpes simplex, Zoster and varicella zoster)	Vaccinia virus	NA		NA	Decrease (99.7 %)	Approved	32708182
DrugRepV_8158	Apigenin	NA	NA	Vaccinia virus	NA		NA	Decrease (54.8 %)	Experimental	32708182
DrugRepV_8159	Avasimibe	NA	Peripheral vascular disease	Vaccinia virus	NA		NA	Decrease (50.9 %)	Investigational	32708182
DrugRepV_8160	Cyclosporin A	NA	Bone marrow transplant rejection	Vaccinia virus	NA		NA	Decrease (67.2 %)	Approved, Investigational, Vet approved	32708182
DrugRepV_8161	ML130	NA	NA	Vaccinia virus	NA		NA	Decrease (35.9 %)	NA	32708182
DrugRepV_8162	PAC-1	NA	Lymphoma, Melanoma, Solid Tumors, Breast Cancer, and Thoracic Cancers	Vaccinia virus	NA		NA	Decrease (95.5 %)	Investigational	32708182
DrugRepV_8163	ABT-263	NA	Solid Tumors, Non-Hodgkin's Lymphoma, EGFR Activating Mutation, Chronic Lymphoid Leukemia, and Hematological Malignancies	Vaccinia virus	NA		NA	Decrease (33.1 %)	Investigational	32708182
DrugRepV_8164	ABT-737	NA	NA	Vaccinia virus	NA		NA	Decrease (26.6 %)	NA	32708182
DrugRepV_8165	PF-2545920	NA	NA	Vaccinia virus	NA		NA	Decrease (33.7 %)	NA	32708182
DrugRepV_8166	Cladribine	Antineoplastic and Immunomodulating Agents	Lymphoproliferative diseases	Vaccinia virus	NA		NA	Decrease (99.8 %)	Approved	32708182
DrugRepV_8167	Adefovir dipivoxil	Antiinfectives For Systemic Use	Hepatitis B virus	Vaccinia virus	NA		NA	Decrease (99.8 %)	Approved	32708182
DrugRepV_8168	TPCA-1	NA	NA	Vaccinia virus	NA		NA	Decrease (78.5 %)	NA	32708182
DrugRepV_8169	Mycophenolic Acid	Immunosuppressant	Organ rejection (immunosuppressants)	Vaccinia virus	NA		NA	Decrease (96.7 %)	Approved, Investigational	32708182
DrugRepV_8170	PTC-209	NA	NA	Vaccinia virus	NA		NA	Decrease (90.7 %)	NA	32708182
DrugRepV_8171	Selisistat	NA	NA	Vaccinia virus	NA		NA	Decrease (30.5 %)	NA	32708182
DrugRepV_8172	Salinomycin	NA	NA	Vaccinia virus	NA		NA	Decrease (92.5 %)	Vet approved	32708182
DrugRepV_8173	Dapivirine	NA	Acquired immunodeficiency syndrome	Vaccinia virus	NA		NA	Decrease (41.7 %)	Investigational	32708182
DrugRepV_8174	CCG 50014	NA	NA	Vaccinia virus	NA		NA	Decrease (35.8 %)	NA	32708182
DrugRepV_8175	Mocetinostat	NA	Lymphoma, Urothelial Carcinoma, Relapsed and Refractory, Myelodysplastic Syndrome, and Metastatic Leiomyosarcoma	Vaccinia virus	NA		NA	Decrease (46.9 %)	Investigational	32708182
DrugRepV_8176	Atorvastatin Calcium	Cardiovascular agents	Coronary heart disease	Vaccinia virus	NA		NA	Decrease (25.4 %)	Approved	32708182
DrugRepV_8177	UK 383367	NA	NA	Vaccinia virus	NA		NA	Decrease (17 %)	NA	32708182
DrugRepV_8178	Lonafarnib	NA	Solid tumors, leukemia (unspecified), and lung cancer	Vaccinia virus	NA		NA	Decrease (36.2 %)	Investigational	32708182
DrugRepV_8179	BX-912	NA	NA	Vaccinia virus	NA		NA	Decrease (42.3 %)	NA	32708182
DrugRepV_8180	URB597	NA	NA	Vaccinia virus	NA		NA	Decrease (21.7 %)	NA	32708182
DrugRepV_8181	Anagrelide HCl	NA	NA	Vaccinia virus	NA		NA	Decrease (58.4 %)	NA	32708182
DrugRepV_8182	Drospirenone	Genito Urinary System and Sex Hormones	Contraception	Vaccinia virus	NA		NA	Decrease (57.4 %)	Approved	32708182
DrugRepV_8183	Ethinyl estradiol	Antineoplastic and Immunomodulating Agents	Cancer	Vaccinia virus	NA		NA	Decrease (53.3 %)	Approved	32708182
DrugRepV_8184	Norethindrone	Gynaecological-agents	Secondary amenorrhea | Endometriosis | Abnormal uterine bleeding	Vaccinia virus	NA		NA	Decrease (48.4 %)	Approved	32708182
DrugRepV_8185	Ganetespib	NA	BREAST CANCER, Small Cell Lung Cancer, Acute Myeloid Leukaemia, and Myelodysplastic Syndrome	Vaccinia virus	NA		NA	Decrease (99.7 %)	Investigational	32708182
DrugRepV_8186	PF-04929113	NA	Cancer/tumors	Vaccinia virus	NA		NA	Decrease (99.4 %)	Investigational	32708182
DrugRepV_8187	NMS-E973	NA	NA	Vaccinia virus	NA		NA	Decrease (99.1 %)	NA	32708182
DrugRepV_8188	XL888	NA	NA	Vaccinia virus	NA		NA	Decrease (99.6 %)	NA	32708182
DrugRepV_8189	Tanespimycin	NA	Leukemia (myeloid) and solid tumors.	Vaccinia virus	NA		NA	Decrease (99.4 %)	Investigational	32708182
DrugRepV_8190	VER-49009	NA	NA	Vaccinia virus	NA		NA	Decrease (98.9 %)	NA	32708182
DrugRepV_8191	SNX2112	NA	NA	Vaccinia virus	NA		NA	Decrease (99.4 %)	NA	32708182
DrugRepV_8192	BIIB021	NA	Tumors and Lymphoma	Vaccinia virus	NA		NA	Decrease (99.8 %)	Investigational	32708182
DrugRepV_8193	AT13387	Antiinfectives For Systemic Use	Hepatitis C virus	Vaccinia virus	NA		NA	Decrease (99.8 %)	Phase III	32708182
DrugRepV_8194	NVP-BEP800	NA	NA	Vaccinia virus	NA		NA	Decrease (98.8 %)	NA	32708182
DrugRepV_8195	AUY922	NA	Lymphoma, Breast Cancer, Metastatic Disease, Advanced Solid Tumors, and Hematologic Neoplasms	Vaccinia virus	NA		NA	Decrease (99.8 %)	Investigational	32708182
DrugRepV_8196	KW-2478	NA	NA	Vaccinia virus	NA		NA	Decrease (92.7 %)	NA	32708182
DrugRepV_8197	Vincristine	Antineoplastic and Immunomodulating Agents	Cancer (Acute leukemia |Hodgkin's and non-Hodgkin's lymphoma |Neuroblastoma |Rhabdomyosarcoma |Ewing's sarcoma |Wilms' tumor | Multiple myeloma | Chronic leukemias | Thyroid cancer | Brain tumors)	Vaccinia virus	NA		NA	Decrease (96.6 %)	Approved	32708182
DrugRepV_8198	ABT-751	NA	Lung Cancer	Vaccinia virus	NA		NA	Decrease (81.5 %)	Investigational	32708182
DrugRepV_8199	Epothilone A	NA	NA	Vaccinia virus	NA		NA	Decrease (27.3 %)	NA	32708182
DrugRepV_8200	Amygdalin	NA	NA	Vaccinia virus	NA		NA	Decrease (58.3 %)	NA	32708182
DrugRepV_8201	Kaempferol	NA	NA	Vaccinia virus	NA		NA	Decrease (64.7 %)	NA	32708182
DrugRepV_8202	ENMD-2076	NA	Breast cancer, leukemia (unspecified), lung cancer, and solid tumors	Vaccinia virus	NA		NA	Decrease (72.3 %)	Investigational	32708182
DrugRepV_8203	AMG-900	NA	NA	Vaccinia virus	NA		NA	Decrease (50.4 %)	NA	32708182
DrugRepV_8204	MLN8054	NA	Colon Neoplasm, Breast Neoplasm, Bladder Neoplasm, Pancreatic Neoplasm, and Advanced Malignancies	Vaccinia virus	NA		NA	Decrease (36.2 %)	Investigational	32708182
DrugRepV_8205	Ibrutinib	NA	Mantle cell lymphoma	Vaccinia virus	NA		NA	Decrease (74.9 %)	Approved	32708182
DrugRepV_8206	CNX-774	NA	NA	Vaccinia virus	NA		NA	Decrease (70 %)	NA	32708182
DrugRepV_8207	AR-A014418	NA	NA	Vaccinia virus	NA		NA	Decrease (47.9 %)	Experimental	32708182
DrugRepV_8208	CGP 57380	NA	NA	Vaccinia virus	NA		NA	Decrease (58.1 %)	NA	32708182
DrugRepV_8209	Genistein	Antihelmintic	Prostate cancer	Vaccinia virus	NA		NA	Decrease (40.6 %)	Investigational	32708182
DrugRepV_8210	HMN-214	NA	NA	Vaccinia virus	NA		NA	Decrease (58.9 %)	NA	32708182
DrugRepV_8211	TG003	NA	NA	Vaccinia virus	NA		NA	Decrease (46.7 %)	NA	32708182
DrugRepV_8212	Skepinone-L	NA	NA	Vaccinia virus	NA		NA	Decrease (47.1 %)	NA	32708182
DrugRepV_8213	TAK-632	NA	NA	Vaccinia virus	NA		NA	Decrease (65.2 %)	NA	32708182
DrugRepV_8214	YM201636	NA	NA	Vaccinia virus	NA		NA	Decrease (56.3 %)	NA	32708182
DrugRepV_8215	MK-2461	NA	NA	Vaccinia virus	NA		NA	Decrease (57 %)	NA	32708182
DrugRepV_8216	OSI-930	Anticancer	Solid tumors	Vaccinia virus	NA		NA	Decrease (43.5 %)	Investigational	32708182
DrugRepV_8217	SP600125	NA	NA	Vaccinia virus	NA		NA	Decrease (50.5 %)	NA	32708182
DrugRepV_8218	SKI II	NA	NA	Vaccinia virus	NA		NA	Decrease (65.1 %)	NA	32708182
DrugRepV_8219	PKI-402	NA	NA	Vaccinia virus	NA		NA	Decrease (44.9 %)	NA	32708182
DrugRepV_8220	BEZ235	NA	Cancer, Solid Tumor, Renal Cancer, Breast Cancer, and Cowden Syndrome	Vaccinia virus	NA		NA	Decrease (37.4 %)	Investigational	32708182
DrugRepV_8221	WYE-125132	NA	NA	Vaccinia virus	NA		NA	Decrease (67.6 %)	NA	32708182
DrugRepV_8222	OSI-027	NA	NA	Vaccinia virus	NA		NA	Decrease (68.3 %)	Investigational	32708182
DrugRepV_8223	Torin 1	NA	NA	Vaccinia virus	NA		NA	Decrease (57.3 %)	NA	32708182
DrugRepV_8224	Ku-0063794	NA	NA	Vaccinia virus	NA		NA	Decrease (55.3 %)	NA	32708182
DrugRepV_8225	AZD2014	NA	Advanced Gastric Adenocarcinoma	Vaccinia virus	NA		NA	Decrease (70.3 %)	Investigational	32708182
DrugRepV_8226	Nocodazole	Anticancer	NA	Vaccinia virus	NA		NA	Decrease (76.2 %)	Experimental	32708182
DrugRepV_8227	Dasatinib	Antineoplastic and Immunomodulating Agents	Cancer	Vaccinia virus	NA		NA	Decrease (74.2 %)	Approved	32708182
DrugRepV_8228	KX2-391	NA	Colon cancer | Pancreatic cancer | Prostate cancer | Breast cancer	Vaccinia virus	NA		NA	Decrease (65.1 %)	Investigational	32708182
DrugRepV_8229	Bosutinib	Antineoplastic and Immunomodulating Agents	Chronic myelogenous leukemia (CML)	Vaccinia virus	NA		NA	Decrease (81.8 %)	Approved	32708182
DrugRepV_8230	PP1	NA	NA	Vaccinia virus	NA		NA	Decrease (35.8 %)	NA	32708182
DrugRepV_8231	AZ 960	NA	NA	Vaccinia virus	NA		NA	Decrease (82.1 %)	NA	32708182
DrugRepV_8232	LY2784544	NA	Myelofibrosis, Polycythemia Vera, Primary Myelofibrosis, Thrombocythemia, Essential, and Myeloproliferative Disorders	Vaccinia virus	NA		NA	Decrease (65.7 %)	Investigational	32708182
DrugRepV_8233	WHI-P154	NA	NA	Vaccinia virus	NA		NA	Decrease (66.3 %)	NA	32708182
DrugRepV_8234	Cyt387	NA	Polycythemia Vera, Primary Myelofibrosis, Post-Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis (PMF)	Vaccinia virus	NA		NA	Decrease (45.2 %)	Investigational	32708182
DrugRepV_8235	KPT-276	NA	NA	Vaccinia virus	NA		NA	Decrease (27.6 %)	NA	32708182
DrugRepV_8236	KPT-185	NA	NA	Vaccinia virus	NA		NA	Decrease (26.2 %)	NA	32708182
DrugRepV_8237	Phloretin	NA	NA	Vaccinia virus	NA		NA	Decrease (-27 %)	Experimental	32708182
DrugRepV_8238	Ivacaftor	Respiratory System	Cystic fibrosis	Vaccinia virus	NA		NA	Decrease (75.5 %)	Approved	32708182
DrugRepV_8239	Tolbutamide	Alimentary Tract and Metabolism	Type 2 Diabetes Mellitus	Vaccinia virus	NA		NA	Decrease (99.9 %)	Approved, Investigational	32708182
DrugRepV_8240	Fexofenadine Hydrochloride	Respiratory System	Allergic rhinitis	Vaccinia virus	NA		NA	Decrease (10.5 %)	Approved	32708182
DrugRepV_8241	Bergapten	Dermatologicals	Severe Generalized Atopic Dermatitis	Vaccinia virus	NA		NA	Decrease (7.6 %)	Investigational	32708182
DrugRepV_8242	SC144	NA	NA	Vaccinia virus	NA		NA	Decrease (98.4 %)	NA	32708182
DrugRepV_8243	Daidzein	NA	Dietary supplement	Vaccinia virus	NA		NA	Decrease (32.2 %)	Experimental	32708182
DrugRepV_8244	Delanzomib	NA	Solid Tumors, Multiple Myeloma, and Lymphoma, Non-Hodgkin.	Vaccinia virus	NA		NA	Decrease (99.7 %)	Investigational	32708182
DrugRepV_8245	MLN9708	NA	Multiple myeloma	Vaccinia virus	NA		NA	Decrease (99.6 %)	Approved, Investigational	32708182
DrugRepV_8246	Oprozomib	NA	NA	Vaccinia virus	NA		NA	Decrease (99.5 %)	Investigational	32708182
DrugRepV_8247	MG-132	NA	NA	Vaccinia virus	NA		NA	Decrease (98.9 %)	NA	32708182
DrugRepV_8248	MLN2238	NA	Multiple myeloma	Vaccinia virus	NA		NA	Decrease (99.7 %)	Approved, Investigational	32708182
DrugRepV_8249	ONX-0914	NA	NA	Vaccinia virus	NA		NA	Decrease (99.5 %)	NA	32708182
DrugRepV_8250	Amonafide	NA	Breast cancer, ovarian cancer, and prostate cancer	Vaccinia virus	NA		NA	Decrease (99.3 %)	Investigational	32708182
DrugRepV_8251	Teniposide	Antineoplastic and Immunomodulating Agents	Acute lymphoblastic leukaemia	Vaccinia virus	NA		NA	Decrease (97.9 %)	Approved	32708182
DrugRepV_8252	Etoposide	Antineoplastic and Immunomodulating Agents	Cancer	Vaccinia virus	NA		NA	Decrease (60.1 %)	Approved	32708182
DrugRepV_8253	Golvatinib	NA	Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck	Vaccinia virus	NA		NA	Decrease (79.8 %)	Investigational	32708182
DrugRepV_8254	Sorafenib	Antineoplastic and Immunomodulating Agents	Hepatocellular carcinoma | Renal cell carcinoma	Vaccinia virus	NA		NA	Decrease (72.6 %)	Approved, Investigational	32708182
DrugRepV_8255	AG 1296	NA	NA	Vaccinia virus	NA		NA	Decrease (53.2 %)	NA	32708182
DrugRepV_8256	NVP-TAE226	NA	NA	Vaccinia virus	NA		NA	Decrease (91.5 %)	NA	32708182
DrugRepV_8257	Cabozantinib malate	NA	Metastatic medullary thyroid cancer	Vaccinia virus	NA		NA	Decrease (79.3 %)	NA	32708182
DrugRepV_8258	XL-184	NA	Thyroid cancer	Vaccinia virus	NA		NA	Decrease (64.2 %)	Approved, Investigational	32708182
DrugRepV_8259	Linifanib	NA	NA	Vaccinia virus	NA		NA	Decrease (60.5 %)	NA	32708182
DrugRepV_8260	TKI-258	NA	Multiple myeloma and solid tumors	Vaccinia virus	NA		NA	Decrease (67.6 %)	Investigational	32708182
DrugRepV_8261	AZD4547	NA	Cancer	Vaccinia virus	NA		NA	Decrease (81.5 %)	Investigational	32708182
DrugRepV_8262	AG-1024	NA	NA	Vaccinia virus	NA		NA	Decrease (71.8 %)	NA	32708182
DrugRepV_8263	BMS-754807	NA	Solid Tumors	Vaccinia virus	NA		NA	Decrease (61.8 %)	Investigational	32708182
DrugRepV_8264	Afatinib	Antineoplastic And Immunomodulating Agents	Metastatic non-small cell lung cancer	Vaccinia virus	NA		NA	Decrease (95.2 %)	Approved	32708182
DrugRepV_8265	Butein	NA	NA	Vaccinia virus	NA		NA	Decrease (62.6 %)	NA	32708182
DrugRepV_8266	CO-1686 (AVL-301)	NA	Nonsmall Cell Lung Cancer, Non-small Cell Lung Cancer, and Locally Advanced or Metastatic Non-small Cell Lung Cancer	Vaccinia virus	NA		NA	Decrease (74.3 %)	NA	32708182
DrugRepV_8267	PD168393	NA	NA	Vaccinia virus	NA		NA	Decrease (67.2 %)	Experimental	32708182
DrugRepV_8268	PD153035 HCl	NA	NA	Vaccinia virus	NA		NA	Decrease (74.7 %)	NA	32708182
DrugRepV_8269	Gefitinib	Antineoplastic and Immunomodulating Agents	Non-small cell lung cancer	Vaccinia virus	NA		NA	Decrease (91.2 %)	Approved, Investigational	32708182
DrugRepV_8270	Desmethyl Erlotinib	NA	Cancer	Vaccinia virus	NA		NA	Decrease (75.5 %)	Approved, Investigational	32708182
DrugRepV_8271	OSI-420	NA	NA	Vaccinia virus	NA		NA	Decrease (46.7 %)	NA	32708182
DrugRepV_8272	Neratinib	Antineoplastic And Immunomodulating Agents	Breast cancer	Vaccinia virus	NA		NA	Decrease (56.7 %)	Approved, Investigational	32708182
DrugRepV_8273	Erlotinib Hydrochloride	Antineoplastic and Immunomodulating Agents	Cancer	Vaccinia virus	NA		NA	Decrease (66.8 %)	Approved	32708182
DrugRepV_8274	WZ8040	NA	NA	Vaccinia virus	NA		NA	Decrease (96.4 %)	NA	32708182
DrugRepV_8279	Bortezomib	Antineoplastic and Immunomodulating Agents	Multiple myeloma	Chikungunya virus	122508	NA	NA	Decrease (50 %)	Approved	32469886
DrugRepV_8280	Bortezomib	Antineoplastic and Immunomodulating Agents	Multiple myeloma	Chikungunya virus	122508	NA	NA	Decrease (50 %)	Approved	32469886
DrugRepV_8281	Bortezomib	Antineoplastic and Immunomodulating Agents	Multiple myeloma	Chikungunya virus	122508	NA	NA	Decrease (50 %)	Approved	32469886
DrugRepV_8282	1-(2-fluorophenyl)-3-(4-(4-isopentyl-1H-1,2,3-triazol-1-yl)phenyl)urea	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	32435411
DrugRepV_8283	1-(3-fluorophenyl)-3-(4-(4-isopentyl-1H-1,2,3-triazol-1-yl)phenyl)urea	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	32435411
DrugRepV_8284	1-(4-(4-(ethoxymethyl)-1H-1,2,3-triazol-1-yl)phenyl)-3-(3-fluorophenyl)urea	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	32435411
DrugRepV_8285	1-(3-fluorophenyl)-3-(4-(4-(3-oxobutyl)-1H-1,2,3-triazol-1-yl)phenyl)urea	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	32435411
DrugRepV_8286	1-(4-(4-butyl-1H-1,2,3-triazol-1-yl)phenyl)-3-(3-fluorophenyl)urea	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	32435411
DrugRepV_8287	N-(2-(3-(4-(4-butyl-1H-1,2,3-triazol-1-yl)phenyl)ureido)phenyl)methanesulfonamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	32435411
DrugRepV_8288	1-(4-(4-isopentyl-1H-1,2,3-triazol-1-yl)phenyl)-3-o-tolylurea	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	32435411
DrugRepV_8289	1-(4-(4-hexyl-1H-1,2,3-triazol-1-yl)phenyl)-3-(2-(trifluoromethyl)phenyl)urea)	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	32435411
DrugRepV_8290	3-(4-(ethoxymethyl)-1H-1,2,3-triazol-1-yl)-N-(2-morpholinophenyl)benzenesulfonamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	32435411
DrugRepV_8291	ethyl 3-((3-(4-(ethoxymethyl)-1H-1,2,3-triazol-1-yl)phenyl)sulfonamido)benzoate	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	32435411
DrugRepV_8292	3-((3-(4-(ethoxymethyl)-1H-1,2,3-triazol-1-yl)phenyl)sulfonamido)benzoic acid	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	32435411
DrugRepV_8293	3-(4-butyl-1H-1,2,3-triazol-1-yl)-N-(2-(methylsulfonamido)phenyl)benzenesulfonamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	32435411
DrugRepV_8294	Tolcapone	Nervous System	Parkinson's Disease	Ebola virus	NA	NA	NA	Decrease (50 %)	Approved, Withdrawn	32425892
DrugRepV_8295	Tolcapone	Nervous System	Parkinson's Disease	Ebola virus	NA	NA	NA	Decrease (50 %)	Approved, Withdrawn	32425892
DrugRepV_8296	Tolcapone	Nervous System	Parkinson's Disease	Ebola virus	NA	NA	NA	Decrease (50 %)	Approved, Withdrawn	32425892
DrugRepV_8297	Tolcapone	Nervous System	Parkinson's Disease	Ebola virus	NA	NA	NA	Decrease (50 %)	Approved, Withdrawn	32425892
DrugRepV_8298	Gemcitabine	Antineoplastic and Immunomodulating Agents	Ovarian cancer | Non-small cell lung cance | Adenocarcinoma of the pancreas	Enterovirus	NA		NA	Decrease (50 %)	Approved	32424333
DrugRepV_8316	Gemcitabine	Antineoplastic and Immunomodulating Agents	Ovarian cancer | Non-small cell lung cance | Adenocarcinoma of the pancreas	Human immunodeficiency virus	NA		NA	Decrease (50 %)	Approved	31866007
DrugRepV_8317	Roscovitine	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31866007
DrugRepV_8318	Quinacrine	NA	Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions	Human immunodeficiency virus	NA		NA	Decrease (50 %)	Investigational	31866007
DrugRepV_8319	Kenpaullone	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31866007
DrugRepV_8320	SB743921	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31866007
DrugRepV_8321	3-Deazauridine	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31866007
DrugRepV_8322	2’-C-Methylcytidine	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31866007
DrugRepV_8335	Nafamostat	NA	Blood vessel coagulation | Hemorrhagic lesions	SARS Coronavirus-2		NA	NA	Decrease (50 %)	Investigational	32596694
DrugRepV_8336	Camostat	Blood And Blood Forming Organs	Chronic pancreatitis	SARS Coronavirus-2	NA	NA	NA	Decrease (50 %)	Experimental	32596694
DrugRepV_8337	Gabexate	NA	Cancer, ischemia-reperfusion injury, and pancreatitis	SARS Coronavirus-2	NA	NA	NA	Decrease (50 %)	Investigational	32596694
DrugRepV_8338	Nelfinavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	SARS Coronavirus-2	NA	NA	NA	Decrease (100 %)	Approved	32374457
DrugRepV_8451	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Yellow fever virus	YFV17D		NA	Decrease (50 %)	Approved	30699122
DrugRepV_8456	Berberine Chloride	NA	NA	Zika virus	NA	NA	NA	Decrease (50 %)	NA	29844387
DrugRepV_8471	Berberine	NA	Parasitic and fungal infection	Human immunodeficiency virus	NA		NA	Decrease (50 %)	Approved	21295891
DrugRepV_8472	Berberine	NA	Parasitic and fungal infection	Influenza virus	NA		NA	Decrease (50 %)	Approved	30099043
DrugRepV_8473	Ebselen	NA	Meniere Disease, Type 2 Diabetes Mellitus, and Type 1 Diabetes Mellitus	Human immunodeficiency virus	NA		NA	Decrease (50 %)	Investigational	23850693
DrugRepV_8474	2-Phenylbenzo[d]isothiazol-3(2H)-one	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	23850693
DrugRepV_8475	2-Phenylbenzo[d] isoxazol-3(2H)-one	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	23850693
DrugRepV_8476	2-Phenyl isoindolin-1-one	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	23850693
DrugRepV_8477	Chelerythrine chloride	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	23850693
DrugRepV_8478	Nitidine chloride	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	23850693
DrugRepV_8479	Berberine chloride	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	23850693
DrugRepV_8480	Sanguinarine chloride	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	23850693
DrugRepV_8481	Norsanguinarine chloride	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	23850693
DrugRepV_8482	R-Apomorphine hydrochloride	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	23850693
DrugRepV_8483	S-Apomorphine hydrochloride	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	23850693
DrugRepV_8484	R(?)-Propylnorapomorphine hydrochloride	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	23850693
DrugRepV_8485	R(?)-Apocodeine hydrochloride	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	23850693